JP2014001144A - Gpr119 agonist - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a novel therapeutic agent for diabetes.SOLUTION: Provided is a compound represented by the specified general formula (II) or a salt thereof, which is a GPR119 agonist. (In formula (II), Arrepresents a phenyl group or the like which may have a substituent selected from a halogen atom, a nitro group, a cyano group, a Calkyl group, an alkoxycarbonyl group with a Calkoxy, and the like; Rrepresents a Calkyl group; Rrepresents a Calkyl group; and Rand Reach represent a hydrogen atom, a halogen atom, or the like.)

Description

  The present invention relates to GPR119 agonists.

Diabetes mellitus, one of lifestyle-related diseases, has an increasing number of patients worldwide. Treatment methods for diabetes can be divided into diet therapy, exercise therapy, and drug therapy (insulin injection, oral diabetes drug). Oral diabetes drugs include α-glucosidase inhibitors (acarbose, voglibose), insulin resistance improvers (pioglitazone hydrochloride), biguanide preparations (metformin hydrochloride), sulfonylurea preparations (glibenclamide, glimepiride), accelerated insulin secretion promotion An agent (mitiglinide calcium hydrate) is commercially available.
More recently, incretin preparations (exenatide) and DPP IV inhibitors (sitagliptin), which are gastrointestinal hormones that enhance insulin secretion, have been developed and marketed, and SGLT inhibitors have also been developed. Yes.
By the way, GPR119 is a G protein-coupled receptor (GPCR) having N-Oleoylanolamide as an endogenous ligand, and has been reported as a receptor that enhances insulin secretion from pancreatic β cells. (Non-Patent Document 1, Non-Patent Document 2) GPR119 agonists were found to increase the plasma concentration of Glucagon like peptide-1 (GLP-1), one of the incretins in in vivo action. (Non-patent Document 3) and may contribute indirectly to the increase in insulin secretion. Furthermore, the action which suppresses a body weight increase in the high fat diet load rat is reported (nonpatent literature 1), and the possibility of being concerned in energy metabolism is also suggested. For these reasons, GPR119 agonists are expected to be applied not only to the possibility of treating diabetes, but also to lifestyle-related diseases such as obesity and metabolic syndrome.
As GPR119 agonists, Patent Document 1 describes the following compound (A) and the like,

  Patent Document 2 describes the following compound (B) and the like.

The compound (A) and the compound of the present invention represented by the following general formula (I) or (II) have a piperidine ring in the former, whereas the latter has 3,6-dihydro-2H- There is a difference in having a pyridine ring.
On the other hand, the compound (B) has the same 3,6-dihydro-2H-pyridine ring structure as the compound of the present invention represented by the following general formula (I) or (II), but 3,6-dihydro-2H- The 3-position of the pyridine ring is unsubstituted, whereas the compound of the present invention is characterized in that the 3-position is an alkyl group. In addition, although this invention compound represented by postscript general formula (I) or (II) is contained in the range of the compound represented by general formula (I) of patent document 2, 3,6-dihydro-2H There is no description of specific compounds in which the pyridine ring is substituted with an alkyl group or the like.

WO2010 / 008739 WO2010 / 013849

Overton HA et al., Cell Metab. 2006, 3, 167-175. Chu ZL et al., Endocrinology, 2007, 148, 2601-2609. Chu ZL et al., Endocrinology, 2008, 149, 2038-2047.

  An object of the present invention is to provide a compound represented by the following general formula (I) or (II) or a pharmaceutically acceptable salt thereof, and a therapeutic agent for diabetes containing these as active ingredients.

  That is, the present invention relates to a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof.

(In the formula, Ar represents a halogen atom, a nitro group, a cyano group, a hydroxy group, a C _1-8 alkyl group, a C _1-8 alkoxy group, a C _1-8 alkyl group substituted with 1 to 3 halogen atoms, C _1-8 alkoxy group substituted with 1 to 3 halogen atoms, phenyloxy group, alkoxycarbonyl group (the carbon number of alkoxy is 1-8), carboxyl group, carbamoyl group, acyl group (the carbon number of alkyl is 1-8), alkylaminocarbonyl group (alkyl has 1 to 8 carbon atoms), dialkylaminocarbonyl group (alkyl has 2 to 12 carbon atoms), cycloalkylaminocarbonyl group (cycloalkyl has 3 to 8 membered rings) , Alkoxycarbonylmethylcarbonyl group (alkoxy has 1 to 8 carbon atoms), alkylsulfonylmethyl group (alkyl has 1 to 8 carbon atoms), Mino group, C _1-8 alkylamino group, C _2-12 dialkylamino group, C _1-8 alkylsulfonylamino group, acylamino group (the alkyl has 1 to 8 carbon atoms), C _1-8 alkylsulfinyl group, C _1-8 alkylsulfonyl group, cycloalkylsulfonyl group (cycloalkyl is a 3- to 8-membered ring), sulfamoyl group, C _1-8 alkylaminosulfonyl group, C _2-12 dialkylaminosulfonyl group, phenylsulfonyl group and 5 or 6 An aryl group which may be substituted with a substituent selected from a heteroaryl group of a member ring or a 5- or 6-membered heteroaryl group which may have a substituent;
A represents (CH ₂ ) _m , O, NR ⁶ or a bond,
Here, m represents an integer of 1 to 3, R ⁶ represents a hydrogen atom or a C _1-8 alkyl group,
B represents (C (R ⁷ ) H) _n , O or NR ⁸ ;
Here, n represents an integer of 1 to 3, and R ⁷ and R ⁸ represent a hydrogen atom or a C _1-8 alkyl group.
However, when A is O, NR ⁶ or a bond, B is not O or NR ⁸ .
One of X and Y is N and the other is CR ⁹ or X and Y are both N;
Here, R ⁹ is a hydrogen atom, a halogen atom, a hydroxy group, a C _1-8 alkyl group, a C _1-8 alkoxy group, a C _1-8 alkyl group substituted with 1 to 3 halogen atoms, or 1 to 3 _Represents a C _1-8 alkoxy group substituted with one halogen atom,
R ¹ represents C (O) OR ¹⁰ , C (O) R ¹¹ , SO ₂ R ¹² , C (O) NR ¹³ R ¹⁴ , CH ₂ C (O) N (R ¹⁵ ) (R ¹⁶ ), Or a halogen atom, a C _1-8 alkyl group, a C _1-8 alkoxy group, a C _1-8 alkyl group substituted with 1 to 3 halogen atoms, and a C ₁ -substituted with 1 to 3 halogen atoms. _A 5- or 6-membered heteroaryl group which may have a substituent selected from ₈ alkoxy groups (the heteroaryl ring has a carbon atom and a nitrogen atom as ring-constituting atoms, and also has an oxygen atom And may be bonded to the nitrogen atom of the 3,6-dihydro-2H-pyridine ring via the carbon atoms constituting the ring),
Here, R ¹⁰ , R ¹¹ , R ¹² , R ¹³ , R ¹⁴ , R ¹⁵ and R ¹⁶ are C _1-8 alkyl, C _2-8 alkenyl group, C _3-8 cycloalkyl group, phenyl group or phenyl group. _Represents a C _1-8 alkyl group substituted with
R ² represents a C _1-8 alkyl group,
R ³ represents a hydrogen atom or a C _1-8 alkyl group,
R ⁴ and R ⁵ may be the same or different, and may be a hydrogen atom, a halogen atom, a hydroxy group, a C _1-8 alkyl group, a C _1-8 alkoxy group, or a C substituted with 1 to 3 halogen atoms. _It represents a C _1-8 alkoxy group substituted with a _1-8 alkyl group or 1 to 3 halogen atoms. )

  The present invention also relates to a compound represented by the following general formula (II) or a pharmaceutically acceptable salt thereof.

(In the formula, Ar ⁰ is a halogen atom, a nitro group, a cyano group, a hydroxy group, a C _1-8 alkyl group, a C _1-8 alkoxy group, or a C _1-8 alkyl group substituted with 1 to 3 halogen atoms. C _1-8 alkoxy group substituted with 1 to 3 halogen atoms, phenyloxy group, alkoxycarbonyl group (alkoxy has 1 to 8 carbon atoms), carboxyl group, carbamoyl group, acyl group (carbon number of alkyl) 1-8), alkylaminocarbonyl group (alkyl has 1 to 8 carbon atoms), dialkylaminocarbonyl group (alkyl has 2 to 12 carbon atoms), cycloalkylaminocarbonyl group (cycloalkyl has 3 to 8 membered rings) ), Alkoxycarbonylmethylcarbonyl group (alkoxy has 1 to 8 carbon atoms), alkylsulfonylmethyl group (alkyl has 1 to 8 carbon atoms) Amino _{groups, C 1-8} alkylamino _{groups, C 2-12} dialkylamino _{groups, C 1-8} alkylsulfonylamino group, (1-8 carbon atoms in the _alkyl) acylamino _{groups, C 1-8} alkylsulfinyl groups, C _1-8 alkylsulfonyl group, cycloalkylsulfonyl group (cycloalkyl is a 3- to 8-membered ring), sulfamoyl group, C _1-8 alkylaminosulfonyl group, C _2-12 dialkylaminosulfonyl group, phenylsulfonyl group and substituent 1 to 3 substituents selected from a 5- or 6-membered heteroaryl group which may have a phenyl group or a pyridyl group,
R ⁰ represents a C _1-8 alkyl group,
R ⁰² represents a C _1-8 alkyl group,
R ⁰⁴ and R ⁰⁵ may be the same or different, and may be a hydrogen atom, a halogen atom, a hydroxy group, a C _1-8 alkyl group, a C _1-8 alkoxy group, or a C substituted with 1 to 3 halogen atoms. _It represents a C _1-8 alkoxy group substituted with a _1-8 alkyl group or 1 to 3 halogen atoms. )

The present invention also relates to a therapeutic agent for diabetes containing the compound represented by the above general formula (I) or (II) or a pharmaceutically acceptable salt thereof as an active ingredient.
Furthermore, this invention relates to the GPR119 agonist which contains the compound represented by the said general formula (I) or (II), or its pharmaceutically acceptable salt as an active ingredient.

Next, the present invention will be described in detail.
Of the compounds represented by the above general formula (I), the following are preferable.
(1)
Ar is a halogen atom, nitro group, cyano group, hydroxy group, C _1-8 alkyl group, C _1-8 alkoxy group, C _1-8 alkyl group substituted with 1 to 3 halogen atoms, 1 to 3 C _1-8 alkoxy group, phenyloxy group, alkoxycarbonyl group (alkoxy has 1 to 8 carbon atoms), carboxyl group, carbamoyl group, acyl group (alkyl has 1 to 8 carbon atoms) substituted with a halogen atom of , Alkylaminocarbonyl group (alkyl has 1 to 8 carbon atoms), dialkylaminocarbonyl group (alkyl has 2 to 12 carbon atoms), cycloalkylaminocarbonyl group (cycloalkyl is 3 to 8 membered ring), alkoxycarbonylmethyl A carbonyl group (the alkoxy has 1 to 8 carbon atoms), an alkylsulfonylmethyl group (the alkyl has 1 to 8 carbon atoms), an amino group, C _1-8 alkylamino group, C _2-12 dialkylamino group, C _1-8 alkylsulfonylamino group, acylamino group (the alkyl has 1 to 8 carbon atoms), C _1-8 alkylsulfinyl group, C _1-8 It has an alkylsulfonyl group, a cycloalkylsulfonyl group (cycloalkyl is a 3- to 8-membered ring), a sulfamoyl group, a C _1-8 alkylaminosulfonyl group, a C _2-12 dialkylaminosulfonyl group, a phenylsulfonyl group, and a substituent. A compound represented by the above general formula (I), which is a phenyl group or a pyridyl group, optionally having 1 to 3 substituents selected from a 5- or 6-membered heteroaryl group, or A pharmaceutically acceptable salt.
(2)
Ar is a halogen atom, nitro group, cyano group, C _1-8 alkyl group, alkoxycarbonyl group (alkoxy has 1 to 8 carbon atoms), carboxyl group, alkylaminocarbonyl group (alkyl has 1 to 8 carbon atoms), It has a cycloalkylaminocarbonyl group (cycloalkyl is a 3-8 membered ring), an amino group, a C _1-8 alkylsulfonyl group, a cycloalkylsulfonyl group (cycloalkyl is a 3-8 membered ring), a sulfamoyl group, and a substituent. The compound represented by the said general formula (I) which is the phenyl group which may be substituted by the substituent selected from the heteroaryl group of the 5-membered ring which may be, or its pharmaceutically acceptable salt.
(3)
A compound represented by the above general formula (I), wherein A is O, and B is CH ₂ , or a compound described in (1) or (2) above, or a pharmaceutically acceptable salt thereof.
(4)
A compound represented by the above general formula (I) or a compound described in the above (1) to (3), or a pharmaceutically acceptable salt thereof, wherein X is N and Y is CH.
(5)
A compound represented by R ¹ is C (O) the general formula is ^{OR 10} (I) or the above (1) to (4) compounds according, or a pharmaceutically acceptable salt thereof.
(6)
The compound according to the above (5), wherein R ¹⁰ is a C _1-8 alkyl group, or a pharmaceutically acceptable salt thereof.
(7)
The compound according to the above (5), wherein R ¹⁰ is a C _3-5 alkyl group, or a pharmaceutically acceptable salt thereof.
(8)
R ¹ is a 3-C _1-8 alkyl-1,2,4-oxadiazol-5-yl group, a 5-C _1-8 alkyl-1,2,4-oxadiazol-3-yl group, or 5 -The compound represented by the said general formula (I) which is an ethyl pyrimidin-2-yl group, the compound of the said (1)-(4) description, or its pharmacologically acceptable salt.
(9)
The compound represented by the said general formula (I) whose R < ² > is a methyl group, the compound of the said (1)-(8) description, or its pharmaceutically acceptable salt.
(10)
A compound represented by the above general formula (I), wherein R ³ is a hydrogen atom, a compound described in (1) to (9) above, or a pharmaceutically acceptable salt thereof.
(11)
The compound represented by the general formula (I), the compounds described in the above (1) to (10), or a pharmaceutically acceptable salt thereof, wherein R ⁴ and R ⁵ are a hydrogen atom or a halogen atom.

Among the compounds represented by the above general formula (II), the following are preferable.
(12)
Ar ⁰ is a halogen atom, nitro group, cyano group, C _1-8 alkyl group, alkoxycarbonyl group (alkoxy has 1 to 8 carbon atoms), carboxyl group, alkylaminocarbonyl group (alkyl has 1 to 8 carbon atoms) , Cycloalkylaminocarbonyl group (cycloalkyl is a 3-8 membered ring), amino group, C _1-8 alkylsulfonyl group, cycloalkylsulfonyl group (cycloalkyl is a 3-8 membered ring), sulfamoyl group and substituent Or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, which is a phenyl group optionally substituted with a substituent selected from a heteroaryl group having a 5-membered ring .
(13)
The compound represented by the above general formula (II), the compound described in the above (12), or a pharmaceutically acceptable salt thereof, wherein R ⁰ is a C _3-5 alkyl group.
(14)
The compound represented by the above general formula (II), wherein R ⁰² is a methyl group, the compound described in the above (12) or (13), or a pharmaceutically acceptable salt thereof.
(15)
A compound represented by the above general formula (II), wherein R ⁰⁴ and R ⁰⁵ are a hydrogen atom or a halogen atom, or a compound described in the above (12) to (14), or a pharmaceutically acceptable salt thereof.

Further, as the compound of the present invention, the following compounds are preferable.

4- [2- (4-Methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl (Example 1),
4- [2- [2-Fluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl (Example 5),
4- [2- (2,6-difluoro-4-methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl (Examples) 17),
4- [2- (2,3-Difluoro-4-methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl (Examples) 48),
4- [3-Fluoro-2- [2-fluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carvone Isopropyl acid (Example 59),
4- [2- (4-Methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate (Example 62)
And 4- [2-[(6-Methanesulfonyl-2-methylpyridin-3-yl) oxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylic acid t-Butyl (Example 64).

In the compound represented by the general formula (I) or (II), examples of the halogen atom include a fluorine atom, a chlorine atom, or a bromine atom, and examples of the C _1-8 alkyl group include a methyl group, an ethyl group, Examples include propyl group, i-propyl group, butyl group, t-butyl group, pentyl group, neopentyl group, and hexyl group.
Examples of the 3- to 6-membered cycloalkyl group include a cyclopropyl group, a cyclopentyl group, and a cyclohexyl group.
Examples of the C _1-8 alkoxy group include a methoxy group, an ethoxy group, and a propoxy group. Examples of the C _1-8 alkyl group substituted with 1 to 3 halogen atoms include a chloromethyl group and a fluoromethyl group. Group, 2-fluoroethyl group or trifluoromethyl group, and the C _1-8 alkoxy group substituted with 1 to 3 halogen atoms includes a fluoromethoxy group or a trifluoromethoxy group.
Further, examples of the alkoxycarbonyl group (the alkoxy has 1 to 8 carbon atoms) include a methoxycarbonyl group or an ethoxycarbonyl group, and the acyl group (the alkyl has 1 to 8 carbon atoms) includes an acetyl group and the like. Examples of the alkylaminocarbonyl group (wherein the alkyl has 1 to 8 carbon atoms) include a methylaminocarbonyl group or an ethylaminocarbonyl group, and the dialkylaminocarbonyl group (wherein the alkyl has 2 to 12 carbon atoms) Examples thereof include a dimethylaminocarbonyl group or a diethylaminocarbonyl group. Examples of the cycloalkylaminocarbonyl group (cycloalkyl is a 3- to 8-membered ring) include a cyclopropylaminocarbonyl group and the like, and an alkoxycarbonylmethylcarbonyl group (carbon of alkoxy). The number is 1-8) Is such methoxycarbonylmethyl group or ethoxycarbonylmethyl group and the like.
Examples of the alkylsulfonylmethyl group (wherein the alkyl has 1 to 8 carbon atoms) include a methanesulfonylmethyl group or an ethanesulfonylmethyl group, and the _C1-8 alkylamino group includes a methylamino group or an ethylamino group. _{Examples of} the C _2-12 dialkylamino group include a dimethylamino group and a diethylamino group. Examples of the C _1-8 alkylsulfonylamino group include a methanesulfonylamino group and an ethanesulfonylamino group. An acylamino group (wherein the alkyl has 1 to 8 carbon atoms) includes an acetylamino group.
As the C _1-8 alkylsulfinyl group, and the like methylsulfinyl group or ethylsulfinyl group. Examples of the C _1-8 alkylsulfonyl group, such as methanesulfonyl group or ethanesulfonyl group, and cycloalkyl sulfonyl group Examples of (cycloalkyl is a 3- to 8-membered ring) include a cyclopropylsulfonyl group and a cyclohexylsulfonyl group, and examples of the C _1-8 alkylaminosulfonyl group include a methylaminosulfonyl group and an ethylaminosulfonyl group. _{Examples of} the C _2-12 dialkylaminosulfonyl group include a dimethylaminosulfonyl group and a diethylaminosulfonyl group.
Moreover, a benzyl group etc. are mentioned as _C1-8 alkyl group substituted by the phenyl group.
_{Examples of the} C _2-8 alkenyl group include a vinyl group and a propenyl group.

Examples of the 5- or 6-membered heteroaryl group which may be substituted with the Ar substituent in the general formula (I) include a pyridyl group.
A substituent which is a substituent that the aryl group of Ar in the general formula (I) or the 5- or 6-membered heteroaryl group and the phenyl group or pyridyl group of Ar ^{0 in} the general formula (II) may have; As the 5- or 6-membered heteroaryl group which may have, 1,2,4-triazol-1- which may be substituted with C _1-8 alkyl such as methyl group or ethyl group An yl group, a tetrazol-1-yl group, or a 1,3,4-oxadiazol-2-yl group.

_{Examples of the} C _1-8 alkyl group include a methyl group, an ethyl group, a propyl group, an i-propyl group, a butyl group, a t-butyl group, a pentyl group, a neopentyl group, and a hexyl group.

In the general formula (I), a 5- or 6-membered heteroaryl group of R ¹ (the heteroaryl ring may have a carbon atom and a nitrogen atom as ring-constituting atoms, and may further have an oxygen atom. Preferable examples of the compound (which is bonded to the nitrogen atom of the 3,6-dihydro-2H-pyridine ring via a carbon atom constituting the ring) include a pyrimidyl group and an oxadiazolyl group.

In the compound represented by the above general formula (I) or (II), pharmaceutically acceptable salts include salts with inorganic acids such as hydrochloride, sulfate, hydrobromide, or fumarate. And salts with organic acids such as mesylate.
In the present invention, the compound represented by the general formula (I) or (II) includes a racemate and an optically active substance.
In the present invention, the compound represented by the general formula (I) or (II) includes hydrates and solvates thereof.

Next, the manufacturing method of the compound represented by the said general formula (I) or its pharmacologically acceptable salt is shown.

Below, A is O, B is exemplified (CH _{2) n} manufacturing method but can be produced in a similar manner for other similar compounds.

<Method A>

(In the formula, Halo represents a halogen atom such as chlorine, bromine or iodine, and L represents a halogen atom such as chlorine, bromine or iodine, or a leaving group such as a methanesulfonyloxy group or p-toluenesulfonyloxy group. And Ar, R ¹ , R ² , R ³ , R ⁴ , R ⁵ , X, Y and n are the same as above.)

1) The starting material (a) can be synthesized by a known method (such as M.V.Cheliah et.al., J. Med. Chem., 2007, 50, 5147, WO2006014213), or a method analogous thereto. it can. The starting material (b) can be synthesized by a known method (DJ Wustrow et.al., Synthesis, 1991, 993, etc.) and a method analogous thereto.

2) First step The conversion of the starting material (a) and the starting material (b) into the compound of the general formula (c) by the condensation reaction does not participate in the reaction of toluene, tetrahydrofuran, dioxane, N, N-dimethylformamide, etc. In the presence of a base such as potassium carbonate, cesium carbonate, or sodium carbonate in a solvent, a catalyst such as tetrakis (triphenylphosphine) palladium, [1,1′-bis (diphenylphosphino) ferrocene] palladium (II) dichloride, dichloromethane complex, etc. Can be used. In this case, the reaction temperature is 20 ° C to 110 ° C.

3) Step 2 Conversion of the compound of the general formula (c) into the compound of the general formula (d) is performed in the presence or absence of a base such as pyridine and triethylamine in a solvent such as toluene and dichloromethane. , Methanesulfonyl chloride, p-toluenesulfonyl chloride, thionyl chloride and the like can be reacted.

4) Step 3 Conversion of the compound of the general formula (d) to the compound of the general formula (f) is carried out by using sodium hydride, potassium carbonate, etc. in a solvent not involved in the reaction such as N, N-dimethylformamide, acetone, etc. The reaction can be performed by reacting the compound represented by the general formula (e) in the presence of a base. In this case, the reaction temperature is 0 ° C to 80 ° C.

Further, the conversion of the compound of the general formula (c) into the compound of the general formula (f) can also be performed by the following method B.

<Method B>

(In the formula, Ar, R ¹ , R ² , R ³ , R ⁴ , R ⁵ , X, Y and n are the same as described above.)

1) Step 1 Conversion of the compound of the general formula (c) into the compound of the general formula (f) is carried out by using a solvent such as tetrahydrofuran, dioxane, toluene, etc., in a solvent not involved in the reaction, such as diethyl azodicarboxylate, diisopropyl azodicarboxylate, etc. The reaction can be carried out by reacting the azodicarboxylic acid ester with the compound represented by the general formula (e) in the presence of triphenylphosphine or the like. In this case, the reaction temperature is 0 ° C to 80 ° C.

Moreover, the compound represented by general formula (f) can be manufactured also by the following C method.

<Method C>

(In the formula, Ar, Halo, R ¹ , R ² , R ³ , R ⁴ , R ⁵ , X, Y and n are the same as described above.)

1) First step The conversion of the starting material (a) into the compound of the general formula (g) is performed by the method described in the second step and the third step of the method A or the method described in the first step of the method B. It can be performed in the same way.

2) Second Step The conversion of the compound of the general formula (g) into the compound of the general formula (f) can be performed in the same manner as described in the first step of the method A.

In addition, this invention compound represented by the said general formula (I) or (II) can also be manufactured with reference to said manufacturing method, a postscript Example, and said patent document 1, 2 grade | etc.,.

Next, pharmacological tests are described.
The GPR119 agonist action was examined by measuring the effect of increasing the intracellular cAMP level of the test compound in cells into which human GPR119 was introduced. In addition, the metabolic stability of the test compound in the human liver microsome reaction solution was examined. (Example 78 described later)
From Tables 2 to 4, it was found that the compounds of the present invention have excellent GPR119 agonist activity and hepatic microsomal metabolic stability.
In particular, as is apparent from Table 1, the compound of the present invention described in Example 1 is a comparative compound described in Reference Example 1 or 3-methyl which does not have an alkyl group at the 3-position of the 3,6-dihydro-2H-pyridine ring. As compared with the comparative compound described in Reference Example 2 which is a piperidine derivative, it was revealed that it has excellent GPR119 agonist activity and liver microsomal metabolic stability.

Therefore, the compound of the above general formula (I) or (II) or a pharmaceutically acceptable salt thereof is expected as a therapeutic agent for diabetes because it has excellent GPR119 agonist activity and liver microsomal metabolic stability. Furthermore, it is also expected to be applied to lifestyle-related diseases such as obesity and metabolic syndrome.
The compound of the above general formula (I) or (II), or a pharmaceutically acceptable salt thereof, can also be used in combination with a known therapeutic agent for diabetes.

The compound of the above general formula (I) or (II) or a pharmaceutically acceptable salt thereof can be administered to humans by an appropriate administration method such as oral administration or parenteral administration. It can also be used in combination with other therapeutic agents for diabetes.
For formulation, it can be produced into a dosage form such as a tablet, granule, powder, capsule, suspension, injection, suppository and the like by a conventional method in the technical field of formulation.
For these preparations, for example, in the case of tablets, usual excipients, disintegrants, binders, lubricants, pigments and the like are used. Here, as the excipient, lactose, D-mannitol, crystalline cellulose, glucose and the like, as the disintegrant, starch, carboxymethylcellulose calcium (CMC-Ca), etc., as the lubricant, magnesium stearate, Examples of binders include talc and the like, and hydroxypropylcellulose (HPC), gelatin, polyvinylpyrrolidone (PVP), and the like. Solvents, stabilizers, solubilizers, suspending agents, emulsifiers, soothing agents, buffers, preservatives and the like are used for the preparation of injections.

In general, for adults, about 0.01 mg to 100 mg of the compound of the above general formula (I) or (II), which is an active ingredient in an injection, or a pharmaceutically acceptable salt thereof, is orally administered per day. The daily dose is 1 mg to 2000 mg, but may be increased or decreased depending on the age, symptoms and the like.

EXAMPLES Next, although an Example is given and this invention is demonstrated further in detail, this invention is not limited to these.

4- [2- (4-Methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl under nitrogen atmosphere 5 -Bromo-2- (4-methanesulfonylphenoxymethyl) pyridine (53 mg, 0.155 mmol), 3-methyl-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2- Yl) -3,6-dihydro-2H-pyridine-1-carboxylate t-butyl (50 mg, 0.155 mmol) was dissolved in anhydrous N, N-dimethylformamide (1.5 mL) and [1,1-bis (Diphenylphosphino) ferrocene] dichloropalladium (II) .dichloromethane adduct (6.3 mg, 7.74 μmol) and cesium carbonate (101 mg, 0.309) mol) was added. After stirring with heating at 80 ° C. for 21 hours, the mixture was allowed to cool to room temperature, water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: acetone = 5: 1) to give the title compound (25 mg, yield 35%) as a white amorphous product.

FAB-MS (m / z): 459 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.03 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.8-2.9 (1H, m), 3.03 ( 3H, s), 3.32 (1H, dd, J = 3 Hz, 13 Hz), 3.84 (1H, dd, J = 3 Hz, 13 Hz), 3.8-4.0 (1H, m), 4. 2-4.5 (1H, m), 5.27 (2H, s), 5.9-6.0 (1 H, m), 7.12 (2H, d, J = 8 Hz), 7.44 ( 1H, d, J = 8 Hz), 7.66 (1H, dd, J = 1 Hz, 8 Hz), 7.87 (2H, d, J = 8 Hz), 8.59 (1H, d, J = 1 Hz).

4- [2- (4-Methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylic acid t-butyl hydrobromide 4- [2- (4-Methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl (100 mg, 100 mg, obtained in Example 1) 0.225 mmol) was dissolved in a mixed solution of ethanol (5 mL) -ethyl acetate (5 mL), 48% hydrobromic acid (49.7 μL, 0.225 mmol) was added under ice cooling, and the mixture was stirred at room temperature for 10 minutes. . After evaporating the solvent under reduced pressure, the residue was dissolved in ethanol (1.5 mL), ethyl acetate (1.5 mL) and diethyl ether (4 mL) were added, and the mixture was stirred at room temperature for 2.5 hr. The precipitated crystals were collected by filtration, washed with diethyl ether, and dried under reduced pressure to give the title compound (158 mg, yield 61%) as white crystals.

FAB-MS (m / z): 459 (M (free base) +1)
m. p. : 136-143 ° C
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.07 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.05 ( 3H, s), 3.2-3.4 (1H, m), 3.8-4.1 (2H, m), 4.2-4.7 (1H, m), 5.83 (2H, s), 6.26 (1H, br s), 7.25 (2H, d, J = 9 Hz), 7.93 (2H, d, J = 9 Hz), 8.07 (1H, d, J = 8 Hz) ), 8.37 (1H, d, J = 8 Hz), 8.73 (1H, s).
IR (KBr, cm ⁻¹ ): 2976, 2929, 1693, 1595, 1558, 1496, 1456, 1415, 1394, 1367, 1296, 1248, 1173, 1147, 1092, 1041, 1018, 962, 874, 839, 771 546, 528, 486.

4- [2- (2-Fluoro-4-nitrophenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl

(1) 5-Bromo-2- (2-fluoro-4-nitrophenoxymethyl) pyridine Under a nitrogen atmosphere, 2-fluoro-4-nitrophenol (125 mg, 0.798 mmol), 5-bromopyridine-2-methanol ( 150 mg, 0.798 mmol) and triphenylphosphine (230 mg, 0.878 mmol) were suspended in anhydrous tetrahydrofuran (8 mL). .878 mmol) was added dropwise. After stirring at room temperature for 16 hours, ethyl acetate was added for dilution. After washing with a 1 mol / L sodium hydroxide aqueous solution, it was dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform) to give the title compound (201 mg, yield 77%) as white crystals.

¹ H NMR (CDCl ₃ , 400 MHz) δ: 5.31 (2H, s), 7.11 (1H, t, J = 8 Hz), 7.46 (1H, d, J = 8 Hz), 7.89 ( 1H, dd, J = 2 Hz, 8 Hz), 8.0-8.1 (2H, m), 8.67 (1H, d, J = 2 Hz).

(2) t-butyl 4- [2- (2-fluoro-4-nitrophenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate obtained above 5-bromo-2- (2-fluoro-4-nitrophenoxymethyl) pyridine (200 mg, 0.611 mmol) was used to give the title compound (160 mg, 59% yield) as a yellow oil in the same manner as in Example 1. Obtained as a thing.

¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.03 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.32 ( 1H, dd, J = 3 Hz, 13 Hz), 3.85 (1H, dd, J = 3 Hz, 13 Hz), 3.8-4.0 (1H, m), 4.2-4.5 (1H, m ), 5.36 (2H, s), 5.9-6.0 (1H, m), 7.15 (1H, t, J = 8 Hz), 7.49 (1H, d, J = 8 Hz), 7.69 (1H, dd, J = 2 Hz, 8 Hz), 8.0-8.1 (2H, m), 8.59 (1H, d, J = 2 Hz).

4- [2- (4-amino-2-fluorophenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl zinc dust (430 mg, 6.58 mmol) was suspended in a 0.5 mol / L hydrochloric acid aqueous solution, stirred at room temperature for 5 minutes, and collected by filtration. The obtained zinc dust and calcium chloride (20 mg, 0.180 mmol) were suspended in a mixed solution of ethanol (12 mL) and water (1 mL), and heated to 90 ° C. T-Butyl 4- [2- (2-fluoro-4-nitrophenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate obtained in Example 3 A solution of (80 mg, 0.180 mmol) in ethanol (6 mL) was added dropwise, heated and stirred at 90 ° C. for 1 hour, allowed to cool to room temperature, and filtered. The filtrate was concentrated under reduced pressure, diluted with ethyl acetate, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 1: 1) to give the title compound (25 mg, yield 34%) as a brown oil.

¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.02 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.8-2.9 (1H, m), 3.32 ( 1H, dd, J = 3 Hz, 13 Hz), 3.52 (2H, brs), 3.84 (1H, dd, J = 3 Hz, 13 Hz), 3.8-4.0 (1H, m), 4 2-4.5 (1H, m), 5.15 (2H, s), 5.9-6.0 (1H, m), 6.3-6.4 (1H, m), 6.48 (1H, dd, J = 2Hz, 12Hz), 6.84 (1H, t, J = 8Hz), 7.54 (1H, d, J = 8Hz), 7.65 (1H, dd, J = 2Hz, 8 Hz), 8.55 (1H, d, J = 2 Hz).

4- [2- [2-Fluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl 4- [2- (4-Amino-2-fluorophenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carvone obtained in Example 4 T-Butyl acid (25 mg, 60.5 μmol) was dissolved in acetic acid and sodium azide (18 mg, 0.272 mmol) and ethyl orthoformate (55 μL, 0.333 mmol) were added. After stirring at 90 ° C. for 2 hours, the mixture was allowed to cool to room temperature, water and a saturated aqueous sodium hydrogen carbonate solution were added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 7: 1 → 0: 100) to give the title compound (10 mg, yield 35%) as white crystals.

FAB-MS (m / z): 467 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.03 (3H, d, J = 7 Hz), 1.52 (9H, s), 2.8-2.9 (1H, m), 3.33 ( 1H, dd, J = 3 Hz, 13 Hz), 3.85 (1H, dd, J = 3 Hz, 13 Hz), 3.8-4.0 (1H, m), 4.2-4.5 (1H, m ), 5.34 (2H, s), 5.8-6.0 (1H, m), 7.23 (1H, t, J = 8 Hz), 7.3-7.5 (1H, m), 7.5-7.6 (2H, m), 7.69 (1H, dd, J = 1 Hz, 8 Hz), 8.59 (1H, d, J = 1 Hz), 8.90 (1H, s).

4- [2- [2-Fluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl Hydrochloride 4- [2- [2-Fluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro obtained in Example 5 -H-pyridine-1-carboxylate t-butyl (100 mg, 0.21 mmol) was dissolved in ethyl acetate (1 mL), 4 mol / L hydrogen chloride-ethyl acetate solution (53 μL, 0.21 mmol) was added, and at room temperature. Stir for 30 minutes. The precipitated crystals were collected by filtration, washed with ethyl acetate, and dried under reduced pressure to give the title compound (53 mg, yield 50%) as white crystals.

FAB-MS (m / z): 467 (M (free base) +1)
¹ H NMR (CD ₃ OD, 400 MHz) δ: 1.06 (3H, d, J = 6 Hz), 1.50 (9H, s), 2.9-3.1 (1H, m), 3.1 -3.4 (1H, m), 3.8-4.0 (2H, m), 4.3-4.5 (1H, m), 5.58 (2H, s), 6.33 (1H) , Br s), 7.52 (1H, t, J = 8 Hz), 7.72 (1H, d, J = 8 Hz), 7.84 (1H, d, J = 1 Hz), 8.08 (1H, d, J = 8 Hz), 8.54 (1H, d, J = 8 Hz), 8.85 (1H, s), 9.70 (1H, s).

4- [2- (2-Fluoro-4-nitrophenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate Example 3 ( 5-Bromo-2- (2-fluoro-4-nitrophenoxymethyl) pyridine (60 mg, 0.183 mmol) and 3-methyl-4- (4,4,5,5-tetramethyl-1) obtained in 1) , 3,2-dioxaborolan-2-yl) -3,6-dihydro-2H-pyridine-1-carboxylate (60 mg, 0.202 mmol) and the title compound (59 mg, Yield 75%) was obtained as yellow crystals.

¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.02 (3H, d, J = 7 Hz), 1.28 (6H, d, J = 6 Hz), 2.8-2.9 (1H, m), 3.37 (1H, dd, J = 3 Hz, 13 Hz), 3.87 (1H, dd, J = 3 Hz, 13 Hz), 3.8-4.0 (1H, m), 4.2-4.5 (1H, m), 4.9-5.0 (1H, m), 5.36 (2H, s), 5.9-6.0 (1H, m), 7.15 (1H, t, J = 8 Hz), 7.50 (1 H, d, J = 8 Hz), 7.69 (1 H, dd, J = 2 Hz, 8 Hz), 8.0-8.1 (2 H, m), 8.59 (1 H) , D, J = 2 Hz).

4- [2- (4-Amino-2-fluorophenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate in Example 7 Obtained isopropyl 4- [2- (2-fluoro-4-nitrophenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate (59 mg, 0.142 mmol) ) Was used to obtain the title compound (55 mg, yield 100%) as a brown amorphous substance in the same manner as in Example 4.

¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.02 (3H, d, J = 7 Hz), 1.2-1.3 (6H, m), 2.8-2.9 (1H, m), 3.3-3.5 (3H, m), 3.87 (1H, dd, J = 3 Hz, 13 Hz), 3.8-4.0 (1H, m), 4.2-4.5 (1H) , M), 4.9-5.0 (1H, m), 5.15 (2H, s), 5.9-6.0 (1H, m), 6.3-6.4 (1H, m ), 6.51 (1 H, dd, J = 2 Hz, 8 Hz), 6.85 (1 H, t, J = 8 Hz), 7.57 (1 H, d, J = 8 Hz), 7.68 (1 H, dd) , J = 2 Hz, 8 Hz), 8.52 (1H, d, J = 2 Hz).

4- [2- [2-fluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate <br> Isopropyl 4- [2- (4-amino-2-fluorophenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate obtained in Example 8 (55 mg, 0.143 mmol) was used to give the title compound (21 mg, yield 33%) as yellow crystals in the same manner as in Example 5.

FAB-MS (m / z): 453 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.03 (3H, d, J = 7 Hz), 1.28 (6H, t, J = 6 Hz), 2.8-2.9 (1H, m), 3.37 (1H, d, J = 13 Hz), 3.87 (1H, dd, J = 3 Hz, 13 Hz), 3.8-4.0 (1H, m), 4.2-4.5 (1H , M), 4.9-5.1 (1H, m), 5.34 (2H, s), 5.9-6.1 (1H, m), 7.23 (1H, t, J = 8 Hz) ), 7.3-7.5 (1H, m), 7.5-7.6 (2H, m), 7.69 (1H, dd, J = 1 Hz, 8 Hz), 8.59 (1H, s) ), 8.90 (1H, s).

4- [2- (4-Methanesulfonylphenoxymethyl) pyridin-5-yl] -3,3-dimethyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl 3,3-dimethyl-4 -(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -3,6-dihydro-2H-pyridine-1-carboxylate t-butyl (50 mg, 0.148 mmol) , 5-bromo-2- (4-methanesulfonylphenoxymethyl) pyridine (51 mg, 0.148 mmol), tetrakis (triphenylphosphine) palladium (0) (9 mg, 0.0078 mmol) and cesium carbonate (72 mg, 0.222 mmol) ) Was suspended in anhydrous N, N-dimethylformamide (2 mL) and stirred at 80 ° C. for 5.5 hours. After cooling to room temperature, water was added and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 3: 2) to give the title compound (37 mg, yield 54%) as pale-yellow crystals.

FAB-MS (m / z): 473 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.05 (6H, s), 1.50 (9H, s), 3.03 (3H, s), 3.3-3.4 (2H, m) , 4.0-4.1 (2H, m), 5.27 (2H, s), 5.4-5.6 (1H, m), 7.13 (2H, d, J = 8 Hz), 7 .42 (1H, d, J = 8 Hz), 7.5-7.6 (1H, m), 7.88 (2H, d, J = 8 Hz), 8.42 (1H, s).

4- [2- (2-Methanesulfonylpyridin-5-yloxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl

(1) 5-Bromo-2- (2-methanesulfonylpyridin-5-yloxymethyl) pyridine 5-hydroxy-2-methanesulfonylpyridine (130 mg, 0.751 mmol) and 5-bromopyridine-2-methanol (141 mg) , 0.751 mmol) and the title compound (204 mg, yield 79%) was obtained in the same manner as in Example 3 (1).

¹ H NMR (CDCl ₃ , 400 MHz) δ: 3.19 (3H, s), 5.27 (2H, s), 7.40 (1H, d, J = 8 Hz), 7.43 (1H, dd, J = 3 Hz, 9 Hz), 7.89 (1H, dd, J = 2 Hz, 8 Hz), 8.04 (1H, d, J = 9 Hz), 8.47 (1H, d, J = 3 Hz), 8. 69 (1H, d, J = 2 Hz).

(2) t-butyl 4- [2- (2-methanesulfonylpyridin-5-yloxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate 5-bromo-2- (2-methanesulfonylpyridin-5-yloxymethyl) pyridine (60 mg, 0.175 mmol), 3-methyl-4- (4,4,5,5-tetramethyl-1) , 3,2-Dioxaborolan-2-yl) -3,6-dihydro-2H-pyridine-1-carboxylate (68 mg, 0.210 mmol) and the title compound (68 mg, 0.210 mmol) in the same manner as in Example 1. 35 mg, 44% yield) was obtained as white crystals.

FAB-MS (m / z): 460 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.03 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.19 ( 3H, s), 3.33 (1H, dd, J = 3 Hz, 13 Hz), 3.8-4.0 (2H, m), 4.1-4.5 (1H, m), 5.32 ( 2H, s), 5.96 (1H, br s), 7.4-7.5 (2H, m), 7.68 (1H, dd, J = 2 Hz, 8 Hz), 8.03 (1H, d , J = 8 Hz), 8.48 (1H, d, J = 2 Hz), 8.60 (1H, s).
IR (KBr, cm ⁻¹ ): 3005, 2974, 2927, 2871, 1691, 1570, 1479, 1450, 1421, 1365, 1308, 1242, 1161, 1130, 1101, 1041, 970, 874, 854, 814, 777 733, 627, 532, 496.

4- [2- (2-Methanesulfonylpyridin-5-yloxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate isopropyl 5-bromo-2- (2-methanesulfonylpyridin-5-yloxymethyl) pyridine (60 mg, 0.175 mmol), 3-methyl-4- (4,4,5,5- The title was prepared in the same manner as in Example 1 using isopropyl tetramethyl-1,3,2-dioxaborolan-2-yl) -3,6-dihydro-2H-pyridine-1-carboxylate (65 mg, 0.210 mmol). The compound (32 mg, yield 41%) was obtained as white crystals.

FAB-MS (m / z): 446 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.03 (3H, d, J = 7 Hz), 1.2-1.4 (6H, m), 2.7-2.9 (1H, m), 3.19 (3H, s), 3.3-3.5 (1H, m), 3.8-4.0 (2H, m), 4.2-4.5 (1H, m), 4. 9-5.1 (1H, m), 5.32 (2H, s), 5.9-6.0 (1H, m), 7.4-7.5 (2H, m), 7.68 ( 1H, dd, J = 2 Hz, 8 Hz), 8.03 (1H, d, J = 9 Hz), 8.48 (1H, d, J = 2 Hz), 8.60 (1H, s).
IR (KBr, cm ⁻¹ ): 2978, 2924, 1685, 1574, 1454, 1429, 1387, 1311, 1236, 1163, 1128, 1101, 1024, 955, 916, 835, 775, 733, 625, 540, 494 418.

4- [2- (2-Methanesulfonylpyrimidin-5-yloxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl

(1) 5-Bromo-2- (2-methylthiopyrimidin-5-yloxymethyl) pyridine 5-hydroxy-2-methylthiopyrimidine (145 mg, 1.02 mmol) and 5-bromopyridine-2-methanol (192 mg, 1 The title compound (255 mg, yield 80%) was obtained in the same manner as in Example 3 (1).

¹ H NMR (CDCl ₃ , 400 MHz) δ: 2.55 (3H, s), 5.18 (2H, s), 7.40 (1H, d, J = 8 Hz), 7.87 (1H, dd, J = 2 Hz, 8 Hz), 8.33 (2H, s), 8.67 (1 H, d, J = 2 Hz).

(2) 5-Bromo-2- (2-methanesulfonylpyrimidin-5-yloxymethyl) pyridine Oxone (registered trademark) (1.00 g, 1.63 mmol) was dissolved in water (8 mL). A solution of 5-bromo-2- (2-methylthiopyrimidin-5-yloxymethyl) pyridine (255 mg, 0.817 mmol) obtained above in methanol (8 mL) was added dropwise over 5 minutes. The mixture was stirred at room temperature for 2 hours, neutralized with a saturated aqueous potassium carbonate solution, water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform: methanol = 98: 2) to obtain the title compound (143 mg, yield 51%).

¹ H NMR (CDCl ₃ , 400 MHz) δ: 3.31 (3H, s), 5.34 (2H, s), 7.40 (1H, d, J = 8 Hz), 7.91 (1H, dd, J = 2 Hz, 8 Hz), 8.63 (2H, s), 8.70 (1 H, d, J = 2 Hz).

(3) t-butyl 4- [2- (2-methanesulfonylpyrimidin-5-yloxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate 5-bromo-2- (2-methanesulfonylpyrimidin-5-yloxymethyl) pyridine (40 mg, 0.116 mmol), 3-methyl-4- (4,4,5,5-tetramethyl-1) , 3,2-Dioxaborolan-2-yl) -3,6-dihydro-2H-pyridine-1-carboxylate (41 mg, 0.128 mmol) and the title compound (41 mg, 0.128 mmol) in the same manner as in Example 1. 34 mg, yield 63%) was obtained as fine brown crystals.

FAB-MS (m / z): 461 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.02 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-3.0 (1H, m), 3.2 3.4 (1H, m), 3.31 (3H, s), 3.7-4.0 (2H, m), 4.2-4.5 (1H, m), 5.38 (2H, s), 5.96 (1H, br s), 7.43 (1H, d, J = 8 Hz), 7.69 (1H, dd, J = 2 Hz, 8 Hz), 8.61 (1H, d, J = 2 Hz), 8.64 (2H, s).
IR (KBr, cm ⁻¹ ): 2974, 2929, 1691, 1560, 1452, 1419, 1390, 1365, 1315, 1296, 1242, 1174, 1130, 1041, 958, 908, 877, 818, 779, 625, 532 505.

4- [2- (5-Methanesulfonylpyridin-2-yloxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl

(1) 5-bromo-2- (5-methanesulfonylpyridin-2-yloxymethyl) pyridine 2-bromo-5-methanesulfonylpyridine (280 mg, 1.19 mmol) and 5-bromopyridine-2-methanol (223 mg) , 1.19 mmol) was dissolved in tetrahydrofuran (3.0 mL) and cooled to -15 ° C. Potassium t-butoxide (1.0 M tetrahydrofuran solution, 1.78 mL, 1.78 mmol) was added dropwise, and the mixture was stirred at 0 ° C. for 4 hours. The reaction mixture was poured into a saturated aqueous ammonium chloride solution and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 1: 1, and chloroform: methanol = 100: 1) to give the title compound (138 mg, yield 34%) as pale yellow crystals. .

¹ H NMR (CDCl ₃ , 400 MHz) δ: 3.08 (3H, s), 5.55 (2H, s), 7.00 (1H, d, J = 8 Hz), 7.35 (1H, d, J = 8 Hz), 7.84 (1H, dd, J = 2 Hz, 8 Hz), 8.09 (1H, dd, J = 2 Hz, 8 Hz), 8.67 (1H, d, J = 2 Hz), 8. 72 (1H, d, J = 2 Hz).

(2) t-butyl 4- [2- (5-methanesulfonylpyridin-2-yloxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate 5-bromo-2- (5-methanesulfonylpyridin-2-yloxymethyl) pyridine (68 mg, 0.198 mmol) and 3-methyl-4- (4,4,5,5-tetramethyl-1 , 3,2-Dioxaborolan-2-yl) -3,6-dihydro-2H-pyridine-1-carboxylate (64 mg, 0.198 mmol) and the title compound (64 mg, 0.198 mmol) in the same manner as in Example 1. 13 mg, 14% yield) was obtained as white crystals.

FAB-MS (m / z): 460 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.02 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.8-2.9 (1H, m), 3.08 ( 3H, s), 3.3-3.4 (1H, m), 3.8-4.0 (2H, m), 4.2-4.5 (1H, m), 5.59 (2H, s), 5.9-6.0 (1H, m), 7.00 (1H, d, J = 8 Hz), 7.40 (1H, d, J = 8 Hz), 7.64 (1H, dd, J = 2 Hz, 8 Hz), 8.08 (1 H, dd, J = 2 Hz, 8 Hz), 8.61 (1 H, s), 8.74 (1 H, d, J = 2 Hz).

4- [2- (5-Methanesulfonylpyridin-2-yloxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate isopropyl 14- (1) 5-bromo-2- (5-methanesulfonylpyridin-2-yloxymethyl) pyridine (70 mg, 0.204 mmol) and 3-methyl-4- (4,4,5,5- The title was prepared in the same manner as in Example 1 using isopropyl tetramethyl-1,3,2-dioxaborolan-2-yl) -3,6-dihydro-2H-pyridine-1-carboxylate (63 mg, 0.204 mmol). The compound (8 mg, 9% yield) was obtained as white crystals.

FAB-MS (m / z): 446 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.02 (3H, d, J = 7 Hz), 1.2-1.3 (6H, m), 2.7-2.9 (1H, m), 3.08 (3H, s), 3.3-3.4 (1H, m), 3.8-4.0 (2H, m), 4.2-4.5 (1H, m), 4. 9-5.1 (1H, m), 5.59 (2H, s), 5.9-6.0 (1 H, m), 7.00 (1 H, d, J = 8 Hz), 7.40 ( 1H, d, J = 8 Hz), 7.64 (1H, dd, J = 2 Hz, 8 Hz), 8.08 (1H, dd, J = 2 Hz, 8 Hz), 8.60 (1H, s), 8. 74 (1H, d, J = 2 Hz).

4- [2- (4-Cyanophenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl

(1) Performed using 4- (5-bromopyridin-2-yl) methoxybenzonitrile 4-hydroxybenzonitrile (190 mg, 1.60 mmol) and 5-bromopyridine-2-methanol (141 mg, 1.60 mmol) The title compound (161 mg, yield 35%) was obtained as white crystals in the same manner as in Example 3 (1).

¹ H NMR (CDCl ₃ , 400 MHz) δ: 5.20 (2H, s), 7.03 (2H, d, J = 9 Hz), 7.39 (1H, d, J = 8 Hz), 7.60 ( 2H, d, J = 9 Hz), 7.86 (1H, dd, J = 2 Hz, 8 Hz), 8.67 (1H, d, J = 2 Hz).

(2) 4- [2- (4-Cyanophenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl obtained above 5-Bromopyridin-2-yl) methoxybenzonitrile (160 mg, 0.553 mmol), 3-methyl-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) The title compound (56 mg, yield 23%) was obtained as white crystals in the same manner as in Example 1 using t-butyl 3,6-dihydro-2H-pyridine-1-carboxylate (197 mg, 0.609 mmol). Obtained.

FAB-MS (m / z): 406 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.02 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-3.0 (1H, m), 3.32 ( 1H, dd, J = 3 Hz, 13 Hz), 3.8-4.0 (2H, m), 4.1-4.5 (1H, m), 5.24 (2H, s), 5.94 ( 1H, br s), 7.05 (2H, d, J = 9 Hz), 7.43 (1H, d, J = 8 Hz), 7.59 (2H, d, J = 9 Hz), 7.66 (1H , Dd, J = 2 Hz, 8 Hz), 8.59 (1H, d, J = 2 Hz).

4- [2- (2,6-difluoro-4-methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl

(1) 5-bromo-2- (2,6-difluoro-4-methanesulfonylphenoxymethyl) pyridine 2,6-difluoro-4-methanesulfonylphenol (120 mg, 0.576 mmol) and 5-bromopyridine-2- The title compound (205 mg, 94% yield) was obtained in the same manner as in Example 3 (1) using methanol (108 mg, 0.576 mmol).

¹ H NMR (CDCl ₃ , 400 MHz) δ: 3.06 (3H, s), 5.37 (2H, s), 7.4-7.6 (3H, m), 7.90 (1H, dd, J = 2 Hz, 8 Hz), 8.64 (1H, d, J = 2 Hz).

(2) t-butyl 4- [2- (2,6-difluoro-4-methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate 5-bromo-2- (2,6-difluoro-4-methanesulfonylphenoxymethyl) pyridine (60 mg, 0.159 mmol), 3-methyl-4- (4,4,5,5-tetramethyl) obtained above. -1,3,2-dioxaborolan-2-yl) -3,6-dihydro-2H-pyridine-1-carboxylate t-butyl (57 mg, 0.175 mmol) in the same manner as in Example 1 The compound (16 mg, yield 20%) was obtained as white crystals.

FAB-MS (m / z): 495 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.02 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.06 ( 3H, s), 3.33 (1H, dd, J = 4 Hz, 13 Hz), 3.8-4.0 (1H, m), 3.84 (1H, dd, J = 3 Hz, 13 Hz), 4. 1-4.5 (1H, m), 5.42 (2H, s), 5.95 (1H, br s), 7.4-7.6 (3H, m), 7.69 (1H, dd) , J = 2 Hz, 8 Hz), 8.56 (1H, d, J = 2 Hz).

4- [2- (2,6-difluoro-4-methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate Implementation 5-Bromo-2- (2,6-difluoro-4-methanesulfonylphenoxymethyl) pyridine (60 mg, 0.159 mmol) obtained in Example 17 (1), 3-methyl-4- (4,4,5,5) Procedure similar to Example 1 using isopropyl 5-tetramethyl-1,3,2-dioxaborolan-2-yl) -3,6-dihydro-2H-pyridine-1-carboxylate (54 mg, 0.175 mmol) Gave the title compound (42 mg, 55% yield) as a pale yellow oil.

FAB-MS (m / z): 481 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.02 (3H, d, J = 7 Hz), 1.2-1.4 (6H, m), 2.7-2.9 (1H, m), 3.05 (3H, s), 3.3-3.5 (1H, m), 3.8-4.0 (1H, m), 3.87 (1H, dd, J = 3 Hz, 13 Hz), 4.2-4.5 (1H, m), 4.9-5.1 (1H, m), 5.41 (2H, s), 5.95 (1H, br s), 7.4-7 .6 (3H, m), 7.69 (1H, dd, J = 2 Hz, 8 Hz), 8.56 (1H, d, J = 2 Hz).

3-Methyl-4- [2- [4- (5-methyl-1,2,4-oxadiazol-3-yl) phenoxymethyl] pyridin-5-yl] -3,6-dihydro-2H-pyridine -1-tert-butyl carboxylate

(1) 4- [2- [4- (N-hydroxycarbamimidoyl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylic acid t- Butyl 4- [2- (4-cyanophenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate obtained in Example 16 (48 mg, 0.118 mmol) was dissolved in ethanol (0.4 mL), 50% aqueous hydroxylamine solution (0.1 mL) was added, and the mixture was stirred at 60 ° C. for 3 hr. After allowing to cool, the solvent was distilled off under reduced pressure to obtain the title compound (50 mg, yield 97%).

¹ H NMR (DMSO-d ₆ , 400 MHz) δ: 0.92 (3H, d, J = 6 Hz), 1.53 (9H, s), 2.8-3.0 (1H, m), 3. 1-3.5 (1H, m), 3.7-3.9 (2H, m), 4.1-4.4 (1H, m), 5.19 (2H, s), 5.69 ( 2H, s), 6.10 (1H, br s), 7.01 (2H, d, J = 9 Hz), 7.49 (1H, d, J = 8 Hz), 7.60 (2H, d, J = 9 Hz), 7.85 (1 H, dd, J = 2 Hz, 8 Hz), 8.62 (1 H, d, J = 2 Hz), 9.45 (1 H, s).

(2) 3-methyl-4- [2- [4- (5-methyl-1,2,4-oxadiazol-3-yl) phenoxymethyl] pyridin-5-yl] -3,6-dihydro- T-butyl 2H-pyridine-1-carboxylate 4- [2- [4- (N-hydroxycarbamimidoyl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6- obtained above. T-Butyl dihydro-2H-pyridine-1-carboxylate (49 mg, 0.112 mmol), acetic acid (6 μL, 0.112 mmol), 1-hydroxybenzotriazole monohydrate (19 mg, 0.123 mmol) in N, Dissolved in N-dimethylformamide (1 mL), and under ice cooling, diisopropylethylamine (64 μL, 0.369 mmol) and 1- (3-dimethylaminopropyl) -3-ethyl After adding lucarbodiimide hydrochloride (26 mg, 0.123 mmol), the mixture was stirred overnight at room temperature. The reaction mixture was poured into saturated aqueous sodium hydrogen carbonate, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The obtained residue was suspended in toluene (2 mL) and heated to reflux for 2 hours. After allowing to cool to room temperature, the solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (chloroform: methanol = 99: 1 → 97: 3) to give the title compound (23 mg, yield 45%) as white crystals. It was.

FAB-MS (m / z): 463 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.03 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.63 (3H, s), 2.7-2.9 ( 1H, m), 3.32 (1H, dd, J = 4 Hz, 13 Hz), 3.7-4.0 (1H, m), 3.84 (1H, dd, J = 3 Hz, 13 Hz), 4. 1-4.5 (1H, m), 5.25 (2H, s), 5.94 (1H, br s), 7.08 (2H, d, J = 9 Hz), 7.48 (1H, d , J = 8 Hz), 7.65 (1H, dd, J = 2 Hz, 8 Hz), 8.00 (2H, d, J = 9 Hz), 8.59 (1H, s).

4- [2- (4-Methoxycarbonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl

(1) Using methyl 4- (5-bromopyridin-2-yl) methoxybenzoate 4-hydroxybenzoate methyl (228 mg, 1.50 mmol) and 5-bromopyridine-2-methanol (282 mg, 1.50 mmol) The title compound (336 mg, yield 70%) was obtained as white crystals in the same manner as in Example 3 (1).

¹ H NMR (CDCl ₃ , 400 MHz) δ: 3.88 (3H, s), 5.21 (2H, s), 6.99 (2H, d, J = 9 Hz), 7.41 (1H, d, J = 8 Hz), 7.85 (1H, dd, J = 2 Hz, 8 Hz), 8.00 (2H, d, J = 9 Hz), 8.67 (1H, d, J = 2 Hz).

(2) 4- [2- (4-Methoxycarbonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl obtained above Methyl (5-bromopyridin-2-yl) methoxybenzoate (224 mg, 0.695 mmol), 3-methyl-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2- Yl) -3,6-dihydro-2H-pyridine-1-carboxylate t-butyl (337 mg, 1.04 mmol) was used to obtain the title compound (139 mg, 46% yield) in the same manner as in Example 1. Obtained as crystals.

FAB-MS (m / z): 439 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.03 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.32 ( 1H, dd, J = 4 Hz, 13 Hz), 3.7-4.0 (1H, m), 3.84 (1H, dd, J = 3 Hz, 13 Hz), 3.88 (3H, s), 4. 1-4.5 (1H, m), 5.25 (2H, s), 5.94 (1H, br s), 7.01 (2H, d, J = 9 Hz), 7.46 (1H, d , J = 8 Hz), 7.65 (1H, dd, J = 2 Hz, 8 Hz), 8.00 (2H, d, J = 9 Hz), 8.59 (1H, d, J = 2 Hz).

3-Methyl-4- [2- [4- (5-methyl-1,3,4-oxadiazol-2-yl) phenoxymethyl] pyridin-5-yl] -3,6-dihydro-2H-pyridine -1-tert-butyl carboxylate

(1) t-butyl 4- [2- (4-hydrazinocarbonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate obtained in Example 20 4- [2- (4-methoxycarbonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl (51 mg, 0.116 mmol) was added. Dissolve in methanol (0.5 mL), add hydrazine monohydrate (45 μL, 0.930 mmol), stir overnight at 45 ° C., add hydrazine monohydrate (180 μL, 3.70 mmol) and add 1 Stir overnight. After allowing to cool to room temperature, the solvent was distilled off under reduced pressure to obtain the title compound (53 mg, quantitative yield).

¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.02 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.2 3.4 (1H, m), 3.8-4.0 (2H, m), 3.9-4.2 (2H, brs), 4.2-4.5 (1H, m), 5 .24 (2H, s), 5.93 (1H, br s), 7.03 (2H, d, J = 9 Hz), 7.20 (1 H, br s), 7.45 (1 H, d, J = 8 Hz), 7.65 (1H, dd, J = 2 Hz, 8 Hz), 7.71 (2H, d, J = 9 Hz), 8.59 (1H, d, J = 2 Hz).

(2) 3-methyl-4- [2- [4- (5-methyl-1,3,4-oxadiazol-2-yl) phenoxymethyl] pyridin-5-yl] -3,6-dihydro- T-butyl 2H-pyridine-1-carboxylate 4- [2- (4-hydrazinocarbonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro- obtained above T-Butyl 2H-pyridine-1-carboxylate (51 mg, 0.116 mmol) and triethyl orthoacetate (0.5 mL) were mixed and stirred at 100 ° C. overnight. After cooling to room temperature, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform: methanol = 99: 1 → 95: 5) to give the title compound (38 mg, 71% yield). Was obtained as white crystals.

FAB-MS (m / z): 463 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.03 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.59 (3H, s), 2.7-2.9 ( 1H, m), 3.32 (1H, dd, J = 4 Hz, 13 Hz), 3.7-4.0 (1H, m), 3.84 (1H, dd, J = 3 Hz, 13 Hz), 4. 1-4.5 (1H, m), 5.26 (2H, s), 5.94 (1H, br s), 7.09 (2H, d, J = 9 Hz), 7.47 (1H, d , J = 8 Hz), 7.66 (1H, dd, J = 2 Hz, 8 Hz), 7.98 (2H, d, J = 9 Hz), 8.59 (1H, d, J = 2 Hz).
IR (KBr, cm ⁻¹ ): 2976, 2927, 1685, 1653, 1614, 1595, 1577, 1502, 1448, 1429, 1381, 1363, 1248, 1174, 1136, 1059, 1030, 985, 957, 879, 845 , 820, 766, 739, 712, 631, 521.

4- [2- (4-Carboxyphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl Obtained in Example 20. 4- [2- (4-Methoxycarbonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl (51 mg, 0.116 mmol) in ethanol (3 mL), 1 M aqueous sodium hydroxide solution (0.61 mL, 0.611 mmol) was added, and the mixture was stirred overnight at room temperature. The mixture was neutralized with 10% aqueous citric acid solution, and the precipitated crystals were collected by filtration, washed with water, and dried under reduced pressure to give the title compound (114 mg, yield 88%) as white crystals.

¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.03 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.2 3.4 (1H, m), 3.7-4.0 (2H, m), 4.1-4.5 (1H, m), 5.27 (2H, s), 5.94 (1H, br s), 7.04 (2H, d, J = 9 Hz), 7.46 (1 H, d, J = 8 Hz), 7.66 (1 H, d, J = 8 Hz), 8.05 (2H, d) , J = 9 Hz), 8.60 (1H, s).

4- [2- [4- (Cyclopropylcarbamoyl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl Example 4- [2- (4-Carboxyphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate (30 mg, 70.7 μmol) obtained in 22. ), Cyclopropylamine (5 μL, 77.7 μmol) and 1-hydroxybenzotriazole monohydrate (12 mg, 77.7 μmol) were dissolved in dichloromethane (1 mL), and N-methylmorpholine (9 μL) was added under ice cooling. , 77.7 μmol) and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (15 mg, 77.7 μmol) And the mixture was stirred overnight at room temperature. The reaction mixture was poured into water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 1: 1 → 1: 3) to give the title compound (22 mg, yield 68%) as white crystals.

FAB-MS (m / z): 464 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 0.5-0.7 (2H, m), 0.8-0.9 (2H, m), 1.02 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-3.0 (2H, m), 3.32 (1H, dd, J = 4 Hz, 13 Hz), 3.7-4.0 (1H, m), 3.84 (1H, dd, J = 3 Hz, 13 Hz), 4.1-4.5 (1 H, m), 5.23 (2 H, s), 5.93 (1 H, br s), 6.12 (1H, s), 7.00 (2H, d, J = 9 Hz), 7.45 (1H, d, J = 8 Hz), 7.64 (1H, dd, J = 2 Hz, 8 Hz), 7.70 (2H, d, J = 9 Hz), 8.57 (1H, d, J = 2 Hz).

3-methyl-4- [2- [4- (1,2,3-triazol-1-yl) phenoxymethyl] pyridin-5-yl] -3,6-dihydro-2H-pyridine-1-carboxylic acid t -Butyl

(1) 5-Bromo-2- [4- (1,2,3-triazol-1-yl) phenoxymethyl] pyridine 4- (1,2,3-triazol-1-yl) phenol (100 mg, 0. 621 mmol) and 5-bromopyridine-2-methanol (117 mg, 0.621 mmol) were used to obtain the title compound (157 mg, yield 76%) in the same manner as in Example 3 (1).

¹ H NMR (DMSO-d ₆ , 400 MHz) δ: 5.26 (2H, s), 7.23 (2H, d, J = 9 Hz), 7.54 (1H, d, J = 8 Hz), 7. 82 (2H, d, J = 9 Hz), 7.93 (1H, d, J = 1 Hz), 8.12 (1H, dd, J = 2 Hz, 8 Hz), 8.71 (1H, d, J = 1 Hz) ), 8.73 (1H, d, J = 2 Hz).

(2) 3-methyl-4- [2- [4- (1,2,3-triazol-1-yl) phenoxymethyl] pyridin-5-yl] -3,6-dihydro-2H-pyridine-1- T-Butyl carboxylate 5-Bromo-2- [4- (1,2,3-triazol-1-yl) phenoxymethyl] pyridine (70 mg, 0.211 mmol), 3-methyl-4- ( Using 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -3,6-dihydro-2H-pyridine-1-carboxylate t-butyl (102 mg, 0.317 mmol) The title compound (44 mg, yield 47%) was obtained as pale-yellow crystals by the same method as in Example 1.

FAB-MS (m / z): 448 (M + 1)
m. p. : 134-138 ° C
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.03 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.33 ( 1H, dd, J = 4 Hz, 13 Hz), 3.7-4.0 (1H, m), 3.85 (1H, dd, J = 3 Hz, 13 Hz), 4.1-4.5 (1H, m ), 5.26 (2H, s), 5.94 (1H, br s), 7.13 (2H, d, J = 9 Hz), 7.48 (1H, d, J = 8 Hz), 7.6 -7.7 (3H, m), 7.83 (1H, s), 7.90 (1H, s), 8.59 (1H, s).
IR (KBr, cm ⁻¹ ): 3149, 3122, 3089, 2966, 2927, 2868, 1685, 1593, 1560, 1520, 1448, 1419, 1363, 1300, 1240, 1182, 1136, 1049, 1030, 984, 876 835, 785, 538.

3-methyl-4- [2- (4-nitrophenoxymethyl) pyridin-5-yl] -3,6-dihydro-2H-pyridine-1-carboxylate t-butyl

(1) Example 3 using 5-bromo-2- (4-nitrophenoxymethyl) pyridine 4-nitrophenol (278 mg, 2.00 mmol) and 5-bromopyridine-2-methanol (376 mg, 2.00 mmol) The title compound (380 mg, yield 61%) was obtained in the same manner as in (1).

¹ H NMR (CDCl ₃ , 400 MHz) δ: 5.25 (2H, s), 7.05 (2H, d, J = 9 Hz), 7.40 (1H, d, J = 8 Hz), 7.87 ( 1H, dd, J = 2 Hz, 8 Hz), 8.21 (2H, d, J = 9 Hz), 8.68 (1H, d, J = 2 Hz).

(2) 3-methyl-4- [2- (4-nitrophenoxymethyl) pyridin-5-yl] -3,6-dihydro-2H-pyridine-1-carboxylate t-butyl 5-bromo obtained above 2- (4-Nitrophenoxymethyl) pyridine (379 mg, 1.23 mmol), 3-methyl-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- The title compound (203 mg, yield 39%) was obtained as pale yellow crystals in the same manner as in Example 1 using t-butyl 3,6-dihydro-2H-pyridine-1-carboxylate (436 mg, 1.23 mmol). Obtained.

¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.03 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.2 3.4 (1H, m), 3.7-4.0 (2H, m), 4.2-4.5 (1H, m), 5.29 (2H, s), 5.95 (1H, br s), 7.07 (2H, d, J = 9 Hz), 7.44 (1H, d, J = 8 Hz), 7.67 (1H, dd, J = 2 Hz, 8 Hz), 8.21 (2H) , D, J = 9 Hz), 8.60 (1H, d, J = 2 Hz).

4- [2- (4-Aminophenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl Obtained in Example 25 Using t-butyl 3-methyl-4- [2- (4-nitrophenoxymethyl) pyridin-5-yl] -3,6-dihydro-2H-pyridine-1-carboxylate (202 mg, 0.475 mmol), The title compound (137 mg, yield 73%) was obtained in the same manner as in Example 4.

¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.02 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.2 3.4 (1H, m), 3.44 (2H, br s), 3.7-4.0 (2H, m), 4.2-4.5 (1H, m), 5.12 (2H , S), 5.92 (1H, br s), 6.64 (2H, d, J = 9 Hz), 6.83 (2H, d, J = 9 Hz), 7.48 (1H, d, J = 8 Hz), 7.63 (1 H, dd, J = 2 Hz, 8 Hz), 8.56 (1 H, d, J = 2 Hz).

3-methyl-4- [2- [4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3,6-dihydro-2H-pyridine-1-carboxylate t-butyl 4- [2- (4-Aminophenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl (40 mg, 0) obtained in Example 26 .101 mmol) and the title compound (29 mg, 63% yield) was obtained as a slightly brown amorphous substance in the same manner as in Example 5.

FAB-MS (m / z): 449 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.03 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.33 ( 1H, dd, J = 4 Hz, 13 Hz), 3.7-4.0 (1H, m), 3.84 (1H, dd, J = 3 Hz, 13 Hz), 4.1-4.5 (1H, m ), 5.27 (2H, s), 5.95 (1H, br s), 7.17 (2H, d, J = 9 Hz), 7.48 (1H, d, J = 8 Hz), 7.60. (2H, d, J = 9 Hz), 7.67 (1H, dd, J = 2 Hz, 8 Hz), 8.60 (1H, d, J = 2 Hz), 8.89 (1H, s).

3-methyl-4- [2- [4- (5-methyltetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3,6-dihydro-2H-pyridine-1-carboxylate t-butyl 4- [2- (4-Aminophenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl obtained in Example 26 ( 40 mg, 0.101 mmol) and triethyl orthoacetate (96 μL, 0.577 mmol) were used in the same manner as in Example 5 to obtain the title compound (7.2 mg, yield: 15%) as fine brown crystals.

FAB-MS (m / z): 463 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.03 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.58 (3H, s), 2.7-2.9 ( 1H, m), 3.33 (1H, dd, J = 4 Hz, 13 Hz), 3.7-4.0 (1H, m), 3.84 (1H, dd, J = 3 Hz, 13 Hz), 4. 1-4.5 (1H, m), 5.27 (2H, s), 5.95 (1H, br s), 7.17 (2H, d, J = 9 Hz), 7.37 (2H, d , J = 9 Hz), 7.48 (1H, d, J = 8 Hz), 7.68 (1H, dd, J = 2 Hz, 8 Hz), 8.60 (1H, d, J = 2 Hz).

4- [3-Chloro-2- [2-fluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carvone T-Butyl acid

(1) 2-fluoro-4- (tetrazol-1-yl) phenol potassium salt 2-fluoro-4- (tetrazol-1-yl) phenol (100 mg, 0.555 mmol) is dissolved in ethanol (2 mL), and 0 0.5 mol / L ethanolic potassium hydroxide solution (1.22 mL) was added. After stirring at room temperature for 1 hour, the solvent was distilled off under reduced pressure to quantitatively obtain the title compound as gray crystals.

(2) 4- [3-chloro-2- (methanesulfonyloxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate in a t-butyl nitrogen atmosphere, 4-[(3-Chloro-2-hydroxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl (83 mg, 0.243 mmol) in dichloromethane (2.5 mL) was dissolved, and triethylamine (51 μL, 0.366 mmol) was added under ice cooling. Subsequently, methanesulfonyl chloride (21 μL, 0.271 mmol) was added dropwise, and the mixture was stirred at room temperature for 3 hours. Then, saturated ammonium chloride aqueous solution was added and extracted with chloroform. The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure to obtain a crude product of the title compound (129 mg) as an orange oil.

(3) 4- [3-Chloro-2- [2-fluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine- The crude 4- [3-chloro-2- (methanesulfonyloxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro- compound obtained above under nitrogen atmosphere of 1-carboxylate t-butyl Dissolve t-butyl 2H-pyridine-1-carboxylate (47 mg) in dimethyl sulfoxide (1 mL), add 2-fluoro-4- (tetrazol-1-yl) phenol potassium salt (25 mg, 0.113 mmol), Stir at room temperature for 1.5 hours. Thereafter, a saturated aqueous ammonium chloride solution was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform to chloroform: methanol = 98: 2) to obtain the title compound (41 mg, yield 73%, 2 steps) as a white amorphous.

FAB-MS (m / z): 501 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.04 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.3 3.4 (1H, m), 3.8-4.0 (2H, m), 4.2-4.5 (1H, m), 5.44 (2H, s), 5.9-6. 1 (1 H, m), 7.34 (1 H, t, J = 9 Hz), 7.41 (1 H, d, J = 9 Hz), 7.51 (1 H, dd, J = 2 Hz, 11 Hz), 7. 69 (1H, d, J = 2 Hz), 8.51 (1 H, d, J = 2 Hz), 8.91 (1 H, s).

4- [3-Chloro-2- [2-fluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carvone Isopropyl acid 4- [3-Chloro-2- [2-fluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3 obtained in Example 29 , 6-Dihydro-2H-pyridine-1-carboxylate t-butyl (30 mg, 0.064 mmol) was dissolved in anhydrous dichloromethane (0.3 mL), and trifluoroacetic acid (0.3 mL) was added dropwise. After stirring at room temperature for 1 hour, the solvent was distilled off under reduced pressure.
Of the resulting 4- [3-chloro-2- [2-fluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine The crude product was dissolved in anhydrous dichloromethane (0.3 mL), triethylamine (45 μL, 0.32 mmol) and isopropyl chloroformate (11 μL, 0.096 mmol) were added under a nitrogen atmosphere, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with water and saturated brine and then dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 1: 2) to give the title compound (26 mg, yield 83%) as white crystals.

FAB-MS (m / z): 487 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.04 (3H, d, J = 7 Hz), 1.2-1.4 (6H, m), 2.7-2.9 (1H, m), 3.3-3.4 (1H, m), 3.8-4.0 (2H, m), 4.3-4.4 (1H, m), 5.0-5.1 (1H, m ), 5.43 (2H, s), 5.9-6.0 (1H, m), 7.3-7.4 (2H, m), 7.47 (1H, dd, J = 2 Hz, 9 Hz) ), 7.67 (1H, d, J = 2 Hz), 8.50 (1H, d, J = 2 Hz), 8.84 (1H, m).

4- [3-Chloro-2- [4- (1,2,4-triazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridin-1 -T -butyl carboxylate Under a nitrogen atmosphere, sodium hydride (2.6 mg, 0.064 mmol) was suspended in anhydrous N, N-dimethylformamide (0.5 mL), cooled to 0 <0> C, An anhydrous N, N-dimethylformamide solution (0.5 mL) of 4- (1,2,4-triazol-1-yl) phenol (9 mg, 0.059 mmol) was added dropwise over 5 minutes. After stirring at room temperature for 30 minutes, 4- [3-chloro-2- (methanesulfonyloxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro- obtained in Example 29 (2) was obtained. An anhydrous N, N-dimethylformamide solution (0.5 mL) of t-butyl 2H-pyridine-1-carboxylate (37 mg, 0.088 mmol) was added dropwise over 5 minutes. After stirring overnight at room temperature, saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform: methanol = 98: 2) to give the title compound (25 mg, yield 87%) as a yellow amorphous.

FAB-MS (m / z): 482 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.04 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.3 3.4 (1H, m), 3.8-4.0 (2H, m), 4.2-4.5 (1H, m), 5.34 (2H, s), 5.9-6. 1 (1H, m), 7.16 (2H, d, J = 9 Hz), 7.58 (2H, d, J = 9 Hz), 7.68 (1H, d, J = 2 Hz), 8.08 ( 1H, s), 8.45 (1H, s), 8.52 (1H, d, J = 2 Hz).

4- [3-Chloro-2- (2,3-difluoro-4-methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylic acid t- Butyl 2,3-difluoro-4-methanesulfonylphenol (13 mg, 0.062 mmol) and 4- [3-chloro-2- (methanesulfonyloxymethyl) pyridin-5-yl] -3-methyl-3,6- The title compound (8 mg, yield 23%) was obtained as a slightly brown amorphous substance in the same manner as in Example 31 using t-butyl dihydro-2H-pyridine-1-carboxylate (39 mg, 0.093 mmol).

FAB-MS (m / z): 529 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.04 (3H, d, J = 7 Hz), 1.49 (9H, s), 2.7-2.9 (1H, m), 3.20 ( 3H, s), 3.3-3.4 (1H, m), 3.8-4.0 (2H, m), 4.2-4.5 (1H, m), 5.45 (2H, s), 5.9-6.1 (1H, m), 7.07 (1H, t, J = 7 Hz), 7.65 (1H, t, J = 7 Hz), 7.69 (1H, d, J = 2 Hz), 8.49 (1H, d, J = 2 Hz).

4- [3-Chloro-2- (4-cyano-3-fluorophenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl 4- Cyano-3-fluorophenol (12 mg, 0.088 mmol) and 4- [3-chloro-2- (methanesulfonyloxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine- Using t-butyl 1-carboxylate (37 mg, 0.088 mmol), the title compound (3 mg, 7% yield) was obtained as a white amorphous substance in the same manner as in Example 29 (1) and Example 29 (3). It was.

FAB-MS (m / z): 458 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.04 (3H, d, J = 7 Hz), 1.49 (9H, s), 2.7-2.9 (1H, m), 3.3 3.4 (1H, m), 3.8-4.0 (2H, m), 4.2-4.5 (1H, m), 5.33 (2H, s), 5.9-6. 1 (1H, m), 6.8-7.0 (2H, m), 7.5-7.6 (1 H, m), 7.68 (1 H, d, J = 2 Hz), 8.50 ( 1H, d, J = 2 Hz).

4- [3-Chloro-2- (2-chloro-4-methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl 2 -Chloro-4-methanesulfonylphenol (21 mg, 0.102 mmol) and 4- [3-chloro-2- (methanesulfonyloxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H- The title compound (9 mg, yield 18%) was obtained as a white amorphous product in the same manner as in Example 31 using t-butyl pyridine-1-carboxylate (32 mg, 0.077 mmol).

FAB-MS (m / z): 527 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.04 (3H, d, J = 7 Hz), 1.49 (9H, s), 2.7-2.9 (1H, m), 3.04 ( 3H, s), 3.3-3.4 (1H, m), 3.8-4.0 (2H, m), 4.2-4.5 (1H, m), 5.45 (2H, s), 5.9-6.1 (1H, m), 7.26 (1H, d, J = 9 Hz), 7.68 (1H, d, J = 2 Hz), 7.78 (1H, dd, J = 2 Hz, 9 Hz), 7.95 (1H, d, J = 2 Hz), 8.50 (1H, d, J = 2 Hz).

4- [3-Chloro-2-[(4-methanesulfonylphenyl) thiomethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl

(1) Dimethylthiocarbamic acid O- (4-methanesulfonylphenyl) ester Under a nitrogen atmosphere, 4-methanesulfonylphenol (150 mg, 0.871 mmol), 1,4-diazabicyclo [2.2.2] octane (195 mg, 1.74 mmol) and dimethylthiocarbamoyl chloride (162 mg, 1.31 mmol) were dissolved in dimethylformamide (4.5 mL) and heated and stirred at 80 ° C. for 5 hours. The mixture was allowed to cool to room temperature, water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The obtained residue was purified by recrystallization (hexane: ethyl acetate: methanol = 5: 1: 1) to give the title compound (49 mg, yield 22%) as white crystals.

¹ H NMR (CDCl ₃ , 400 MHz) δ: 3.09 (3H, s), 3.37 (3H, s), 3.47 (3H, s), 7.27 (2H, d, J = 10 Hz) , 7.98 (2H, d, J = 10 Hz).

(2) 4-Methanesulfonylthiophenol The dimethylthiocarbamic acid O- (4-methanesulfonylphenyl) ester (49 mg, 0.187 mmol) obtained above was heated and stirred at 180 ° C. for 48 hours. The mixture was allowed to cool to room temperature, methanol (2 mL), 1 mol / L aqueous sodium hydroxide solution (2 mL) were added, and the mixture was heated with stirring at 100 ° C. overnight. The mixture was allowed to cool to room temperature, 1 mol / L hydrochloric acid (2 mL) was added, and the solvent was evaporated under reduced pressure. Water was added to the obtained residue, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure to obtain a crude product of the title compound (30 mg) as a colorless oil.

¹ H NMR (CDCl ₃ , 400 MHz) δ: 3.04 (3H, s), 3.71 (1H, s), 7.41 (2H, d, J = 9 Hz), 7.78 (2H, d, J = 9 Hz).

(3) 4- [3-Chloro-2-[(4-methanesulfonylphenyl) thiomethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl Under a nitrogen atmosphere, 4-methanesulfonylthiophenol (30 mg, 0.159 mmol) obtained above, 4- [3-chloro-2- (methanesulfonyloxymethyl) pyridin-5-yl] -3-methyl-3, T-butyl 6-dihydro-2H-pyridine-1-carboxylate (38 mg, 0.092 mmol) and cesium carbonate (78 mg, 0.239 mmol) were dissolved in acetone (1.6 mL) and stirred at room temperature overnight. The solvent was distilled off under reduced pressure, water was added to the obtained residue, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 1: 1 → 2: 3) to give the title compound (4 mg, yield 8%) as a white amorphous product.

FAB-MS (m / z): 509 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.03 (3H, d, J = 7 Hz), 1.49 (9H, s), 2.7-2.9 (1H, m), 3.03 ( 3H, s), 3.2-3.3 (1H, m), 3.8-4.0 (2H, m), 4.2-4.5 (1H, m), 4.48 (2H, s), 5.9-6.1 (1H, m), 7.60 (2H, d, J = 9 Hz), 7.64 (1H, d, J = 2 Hz), 7.81 (2H, d, J = 9 Hz), 8.42 (1H, d, J = 2 Hz).

4- [3-Chloro-2- (2-fluoro-4-methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl 2 -Fluoro-4-methanesulfonylphenol (35 mg, 0.184 mmol) and 4- [3-chloro-2- (methanesulfonyloxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H- Using t-butyl pyridine-1-carboxylate (37 mg, 0.088 mmol), the title compound (31 mg, 69% yield) was converted to a white amorphous substance in the same manner as in Example 29 (1) and Example 29 (3). Got as.

FAB-MS (m / z): 511 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.04 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.04 ( 3H, s), 3.30 (1H, dd, J = 4 Hz, 13 Hz), 3.8-4.0 (1H, m), 3.85 (1H, dd, J = 4 Hz, 13 Hz), 4. 2-4.5 (1H, m), 5.43 (2H, s), 6.01 (1H, br s), 7.30 (1 H, t, J = 8 Hz), 7.6-7.7 (3H, m), 8.50 (1H, d, J = 2 Hz).

4- [3-Chloro-2- (4-sulfamoylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl 4-hydroxybenzene Sulfonamide potassium salt (37 mg, 0.177 mmol) and 4- [3-chloro-2- (methanesulfonyloxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridin-1- The title compound (21 mg, yield 47%) was obtained as a white amorphous substance in the same manner as in Example 29 (3) using t-butyl carboxylate (37 mg, 0.088 mmol).

FAB-MS (m / z): 494 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.04 (3H, d, J = 7 Hz), 1.49 (9H, s), 2.7-2.9 (1H, m), 3.30 ( 1H, dd, J = 3 Hz, 13 Hz), 3.7-4.0 (1H, m), 3.85 (1H, dd, J = 3 Hz, 13 Hz), 4.1-4.5 (1H, m ), 4.89 (2H, br s), 5.34 (2H, s), 6.00 (1H, br s), 7.11 (2H, d, J = 9 Hz), 7.68 (1H, d, J = 2 Hz), 7.86 (2H, d, J = 9 Hz), 8.51 (1H, d, J = 2 Hz).

4- [3-Chloro-2- (2,6-difluoro-4-methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylic acid t- Butyl 2,6-difluoro-4-methanesulfonylphenol (11 mg, 0.053 mmol) and 4- [3-chloro-2- (methanesulfonyloxymethyl) pyridin-5-yl] -3-methyl-3,6- The title compound (8 mg, yield 30%) was prepared in the same manner as in Example 29 (1) and Example 29 (3) using t-butyl dihydro-2H-pyridine-1-carboxylate (22 mg, 0.053 mmol). ) Was obtained as a pale yellow oil.

FAB-MS (m / z): 529 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.04 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.07 ( 3H, s), 3.31 (1H, dd, J = 3 Hz, 13 Hz), 3.8-4.0 (1H, m), 3.85 (1H, dd, J = 3 Hz, 13 Hz), 4. 2-4.5 (1H, m), 5.53 (2H, s), 6.03 (1H, br s), 7.4-7.6 (2H, m), 7.68 (1H, d , J = 2 Hz), 8.47 (1H, d, J = 2 Hz).

4- [3-Chloro-2- (3-fluoro-4-methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl 3 -Fluoro-4-methanesulfonylphenol (14 mg, 0.071 mmol) and 4- [3-chloro-2- (methanesulfonyloxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H- The title compound (20 mg, yield 56%) was pale yellow in the same manner as in Example 29 (1) and Example 29 (3) using t-butyl pyridine-1-carboxylate (29 mg, 0.069 mmol). Obtained as amorphous.

FAB-MS (m / z): 511 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.04 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.18 ( 3H, s), 3.31 (1H, dd, J = 4 Hz, 13 Hz), 3.8-4.0 (1H, m), 3.85 (1H, dd, J = 4 Hz, 13 Hz), 4. 2-4.5 (1H, m), 5.35 (2H, s), 6.01 (1H, br s), 6.8-7.0 (2H, m), 7.69 (1H, d , J = 2 Hz), 7.86 (1H, t, J = 9 Hz), 8.51 (1H, d, J = 2 Hz).

4- [3-Chloro-2- (2,3-difluoro-4-nitrophenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl 2,3-difluoro-4-nitrophenol (53 mg, 0.300 mmol) and 4- [3-chloro-2- (methanesulfonyloxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro- The title compound (32 mg, 27% yield) was obtained in the same manner as in Example 29 (1) and Example 29 (3) using t-butyl 2H-pyridine-1-carboxylate (100 mg, 0.239 mmol). Obtained as a pale yellow oil.

¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.04 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.30 ( 1H, dd, J = 3Hz, 13Hz), 3.8-4.0 (1H, m), 3.85 (1H, dd, J = 3Hz, 13Hz), 4.0-4.5 (1H, m ), 5.48 (2H, s), 6.01 (1H, br s), 7.0-7.1 (1H, m), 7.69 (1H, d, J = 2 Hz), 7.8 −8.0 (1H, m), 8.49 (1H, d, J = 2 Hz).

4- [2- (4-Amino-2,3-difluorophenoxymethyl) -3-chloropyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl 4- [3-Chloro-2- (2,3-difluoro-4-nitrophenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H obtained in Example 40 -The title compound (19 mg, 62% yield) was obtained as a yellow oil in the same manner as in Example 4 using t-butyl pyridine-1-carboxylate (32 mg, 0.065 mmol).

¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.03 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.31 ( 1H, dd, J = 3 Hz, 13 Hz), 3.57 (2H, br s), 3.8-4.0 (1 H, m), 3.85 (1 H, dd, J = 3 Hz, 13 Hz), 4 1-4.5 (1H, m), 5.25 (2H, s), 5.99 (1H, br s), 6.4-6.5 (1H, m), 6.7-6. 8 (1H, m), 7.65 (1 H, s), 8.50 (1 H, s).

4- [3-Chloro-2- [2,3-difluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1 -T -Butyl carboxylate 4- [2- (4-Amino-2,3-difluorophenoxymethyl) -3-chloropyridin-5-yl] -3-methyl-3 obtained in Example 41 , 6-Dihydro-2H-pyridine-1-carboxylate t-butyl (19 mg, 0.040 mmol) was used to obtain the title compound (12 mg, 57% yield) as a pale yellow amorphous product in the same manner as in Example 5. It was.

FAB-MS (m / z): 519 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.05 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.31 ( 1H, dd, J = 4 Hz, 13 Hz), 3.8-4.0 (1H, m), 3.86 (1H, dd, J = 4 Hz, 13 Hz), 4.2-4.5 (1H, m ), 5.46 (2H, s), 6.02 (1H, br s), 7.1-7.2 (1H, m), 7.5-7.6 (1H, m), 7.70. (1H, d, J = 2 Hz), 8.51 (1H, d, J = 2 Hz), 9.01 (1H, d, J = 2 Hz).

4- [3-Chloro-2- [2-fluoro-4- (1,2,4-triazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H -Pyridine -1-carboxylate t-butyl 2-fluoro-4- (1,2,4-triazol-1-yl) phenol (18 mg, 0.098 mmol) and 4- [3-chloro-2- (methanesulfonyl) Oxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl (37 mg, 0.089 mmol) was used in the same manner as in Example 31. The compound (13 mg, yield 29%) was obtained as a white amorphous.

FAB-MS (m / z): 500 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.05 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.2 3.4 (1H, m), 3.8-4.0 (2H, m), 4.2-4.5 (1H, m), 5.40 (2H, s), 6.01 (1H, br s), 7.2-7.3 (1 H, m), 7.3-7.4 (1 H, m), 7.48 (1 H, dd, J = 2 Hz, 11 Hz), 7.68 (1 H , D, J = 2 Hz), 8.08 (1H, s), 8.47 (1H, s), 8.51 (1H, d, J = 2 Hz).

4- [3-Chloro-2- (3-fluoro-4-nitrophenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl 3- Fluoro-4-nitrophenol (31 mg, 0.20 mmol) and 4- [3-chloro-2- (methanesulfonyloxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine- The title compound (58 mg, yield 69%) was obtained as a white amorphous substance using t-butyl 1-carboxylate (74 mg, 0.18 mmol) in the same manner as in Example 29 (1) and Example 29 (3). It was.

¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.04 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.2 3.4 (1H, m), 3.7-4.0 (2H, m), 4.2-4.5 (1H, m), 5.37 (2H, s), 6.01 (1H, br s), 6.8-7.0 (2H, m), 7.69 (1H, d, J = 2 Hz), 8.0-8.2 (1H, m), 8.51 (1H, d) , J = 2 Hz).

4- [2- (4-Amino-3-fluorophenoxymethyl) -3-chloropyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl Example 4- [3-Chloro-2- (3-fluoro-4-nitrophenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylic acid obtained in 44 The title compound (54 mg, yield 100%) was obtained as a brown amorphous substance in the same manner as in Example 4 using t-butyl (58 mg, 0.12 mmol).

¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.03 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.2 3.4 (1H, m), 3.8-4.0 (2H, m), 4.2-4.5 (1H, m), 5.20 (2H, s), 5.98 (1H, br s), 6.6-6.8 (3H, m), 7.66 (1H, s), 8.56 (1H, s).

4- [3-Chloro-2- [3-fluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carvone T-Butyl acid 4- [2- (4-Amino-3-fluorophenoxymethyl) -3-chloropyridin-5-yl] -3-methyl-3,6- obtained in Example 45. The title compound (40 mg, 67% yield) was obtained as a pale yellow amorphous product in the same manner as in Example 5 using t-butyl dihydro-2H-pyridine-1-carboxylate (54 mg, 0.12 mmol).

FAB-MS (m / z): 501 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.04 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.2 3.4 (1H, m), 3.8-4.0 (2H, m), 4.2-4.5 (1H, m), 5.36 (2H, s), 6.02 (1H, br s), 7.0-7.1 (2H, m), 7.70 (1 H, d, J = 2 Hz), 7.7-7.9 (1 H, m), 8.52 (1 H, d) , J = 2 Hz), 8.99 (1H, d, J = 2 Hz).

4- [2- [2-Fluoro-4- (1,2,4-triazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1 -T-butyl carboxylate

(1) 5-Bromo-2-methanesulfonyloxymethylpyridine In a nitrogen atmosphere, 5-bromopyridine-2-methanol (80 mg, 0.425 mmol) was dissolved in dichloromethane (4.2 mL), and triethylamine ( 177 μL, 1.27 mmol) was added. Subsequently, methanesulfonyl chloride (50 μL, 0.646 mmol) was added dropwise, and the mixture was stirred overnight at room temperature. A saturated aqueous ammonium chloride solution was added, and the mixture was extracted with chloroform. The organic layer was washed with saturated brine, and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure to obtain a crude title compound (59 mg) as light brown crystals.

(2) 5-Fluoro-2- [2-fluoro-4- (1,2,4-triazol-1-yl) phenoxymethyl] pyridine under nitrogen atmosphere, 2-fluoro-4- (1,2,4- Title compound in the same manner as in Example 31 using triazol-1-yl) phenol (76 mg, 0.425 mmol) and 5-bromo-2-methanesulfonyloxymethylpyridine (59 mg, 0.223 mmol) obtained above. (67 mg, 45% yield, 2 steps) was obtained as white crystals.

¹ H NMR (CDCl ₃ , 400 MHz) δ: 5.27 (2H, s), 7.12 (1H, t, J = 9 Hz), 7.36 (1H, d, J = 9 Hz), 7.5− 7.6 (2H, m), 7.88 (1H, dd, J = 2 Hz, 8 Hz), 8.08 (1H, s), 8.46 (1H, s), 8.67 (1H, d, J = 2 Hz).

(3) 4- [2- [2-Fluoro-4- (1,2,4-triazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H- 5-Bromo-2- [2-fluoro-4- (1,2,4-triazol-1-yl) phenoxymethyl] pyridine (30 mg, obtained above) in a t-butyl nitrogen atmosphere of pyridine-1-carboxylate 0.086 mmol) and 3-methyl-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -3,6-dihydro-2H-pyridine-1-carboxylic acid The title compound (8 mg, yield 21%) was obtained as pale brown crystals in the same manner as in Example 1 using t-butyl (28 mg, 0.086 mmol).

FAB-MS (m / z): 466 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.03 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.3 3.4 (1H, m), 3.8-4.0 (2H, m), 4.2-4.5 (1H, m), 5.31 (2H, s), 5.9-6. 1 (1 H, m), 7.15 (1 H, t, J = 9 Hz), 7.35 (1 H, d, J = 9 Hz), 7.49 (1 H, d, J = 2 Hz), 7.53 ( 1H, d, J = 8 Hz), 7.68 (1H, dd, J = 2 Hz, 8 Hz), 8.08 (1H, s), 8.46 (1H, s), 8.59 (1H, d, J = 2 Hz).

4- [2- (2,3-Difluoro-4-methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl

(1) 5-Bromo-2- (2,3-difluoro-4-methanesulfonylphenoxymethyl) pyridine 2,3-difluoro-4-methanesulfonylphenol (44 mg, 0.213 mmol) and 5-bromo-2-methane The title compound (32 mg, 40% yield) was obtained as pale yellow crystals in the same manner as in Example 29 (1) and Example 29 (3) using sulfonyloxymethylpyridine (48 mg, 0.180 mmol).

¹ H NMR (CDCl ₃ , 400 MHz) δ: 3.20 (3H, s), 5.30 (2H, s), 6.9-7.0 (1H, m), 7.44 (1H, d, J = 8 Hz), 7.6-7.7 (1 H, m), 7.90 (1 H, dd, J = 2 Hz, 8 Hz), 8.68 (1 H, d, J = 2 Hz).

(2) t-butyl 4- [2- (2,3-difluoro-4-methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate Under a nitrogen atmosphere, 5-bromo-2- (2,3-difluoro-4-methanesulfonylphenoxymethyl) pyridine (32 mg, 0.085 mmol) and 3-methyl-4- (4,4,5,) obtained above were obtained. Similar to Example 1 using t-butyl 5-tetramethyl-1,3,2-dioxaborolan-2-yl) -3,6-dihydro-2H-pyridine-1-carboxylate (27 mg, 0.085 mmol) The title compound (9 mg, 21% yield) was obtained as pale yellow crystals by the above procedure.

FAB-MS (m / z): 495 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.03 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.20 ( 3H, s), 3.3-3.4 (1H, m), 3.8-4.0 (2H, m), 4.2-4.5 (1H, m), 5.35 (2H, s), 5.9-6.1 (1H, m), 6.9-7.0 (1H, m), 7.48 (1H, d, J = 8 Hz), 7.7-7.6 ( 2H, m), 8.59 (1H, d, J = 2 Hz).

4- [2- (2,3-difluoro-4-methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylic acid t-butyl hydrochloride < 4- [2- (2,3-difluoro-4-methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1 obtained in Example 48 -The title compound (179 mg, 84% yield) was obtained as pale-brown crystals in the same manner as in Example 6 using t-butyl carboxylate (193 mg, 0.400 mmol).

FAB-MS (m / z): 495 (M (free base) +1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.07 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.23 ( 3H, s), 3.3-3.4 (1H, m), 3.8-4.1 (2H, m), 4.2-4.6 (1H, m), 5.87 (2H, s), 6.24 (1H, br s), 7.1-7.3 (1H, m), 7.7-7.8 (1H, m), 8.11 (1H, d, J = 9 Hz) ), 8.36 (1H, d, J = 8 Hz), 8.66 (1H, s).
IR (KBr, cm ⁻¹ ): 3006, 2976, 2927, 2391, 2085, 1982, 1697, 1649, 1610, 1560, 1508, 1466, 1412, 1367, 1319, 1248, 1173, 1140, 1084, 1039, 989 , 876,827,775,521,492.

4- [2- (2,3-Difluoro-4-methanesulfonylphenoxymethyl) pyridin-5-yloxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridin-1- Isopropyl carboxylate 5-Bromo-2- (2,3-difluoro-4-methanesulfonylphenoxymethyl) pyridine (60 mg, 0.159 mmol), 3-methyl-4 obtained in Example 48 (1) -Using isopropyl (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -3,6-dihydro-2H-pyridine-1-carboxylate (54 mg, 0.175 mmol) The title compound (31 mg, yield 40%) was obtained as white crystals in the same manner as in Example 1.

FAB-MS (m / z): 481 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.03 (3H, d, J = 7 Hz), 1.2-1.4 (6H, m), 2.7-2.9 (1H, m), 3.20 (3H, s), 3.3-3.5 (1H, m), 3.8-4.0 (2H, m), 4.2-4.5 (1H, m), 4. 9-5.1 (1H, m), 5.35 (2H, s), 5.96 (1H, br s), 6.9-7.1 (1H, m), 7.48 (1H, d , J = 8 Hz), 7.6-7.8 (2H, m), 8.59 (1H, s).
IR (KBr, cm ⁻¹ ): 2976, 2929, 1691, 1624, 1510, 1468, 1427, 1389, 1311, 1267, 1234, 1169, 1136, 1088, 1028, 987, 962, 916, 897, 850, 812 , 764,652,604,519,490.

5-ethyl-2- [4- [2- [2-fluoro-4- (1,2,4-triazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6- Dihydro-2H-pyridin-1-yl] pyrimidine 4- [2- [2-Fluoro-4- (1,2,4-triazol-1-yl) phenoxymethyl] pyridine obtained in Example 47 -5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl (18 mg, 0.038 mmol) was dissolved in dichloromethane (1 mL), and trifluoroacetic acid was cooled with ice. (175 μL) was added dropwise. After stirring at room temperature for 30 minutes, the reaction mixture was concentrated under reduced pressure.
Subsequently, the obtained 4- [2- [2-fluoro-4- (1,2,4-triazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-1 was obtained under a nitrogen atmosphere. , 2, 3, 6-tetrahydropyridine was dissolved in acetonitrile (1 mL), and potassium carbonate (26 mg, 0.190 mmol) and 2-chloro-5-ethylpyrimidine (4.5 μL,. 076 mmol) was added, and the mixture was stirred with heating at 80 ° C. overnight. The mixture was allowed to cool to room temperature, water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The obtained residue was purified by thin layer chromatography (chloroform: methanol = 10: 1) to obtain the title compound (6 mg, yield 35%) as pale yellow crystals.

FAB-MS (m / z): 472 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.07 (3H, d, J = 7 Hz), 1.21 (3H, t, J = 7 Hz), 2.49 (2H, q, J = 7 Hz), 2.9-3.0 (1H, m), 3.6-3.7 (1H, m), 4.1-4.2 (1H, m), 4.3-4.4 (1H, m ), 4.5-4.7 (1H, m), 5.32 (2H, s), 6.0-6.1 (1H, m), 7.15 (1H, t, J = 8 Hz), 7.35 (1H, d, J = 9 Hz), 7.5-7.6 (2H, m), 7.72 (1H, dd, J = 2 Hz, 8 Hz), 8.08 (1H, s), 8.22 (2H, s), 8.45 (1H, s), 8.63 (1H, d, J = 2 Hz).

4- [3-Fluoro-2- (4-methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl 5-bromo-3 -Fluoro-2- (4-methanesulfonylphenoxymethyl) pyridine (26 mg, 72.2 μmol), 3-methyl-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2- Yl) -3,6-dihydro-2H-pyridine-1-carboxylate t-butyl (26 mg, 79.4 μmol) and the title compound (24 mg, 70% yield) in the same manner as in Example 1. Obtained as a white amorphous.

FAB-MS (m / z): 477 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.05 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.03 ( 3H, s), 3.31 (1H, dd, J = 3 Hz, 13 Hz), 3.86 (1H, dd, J = 3 Hz, 13 Hz), 3.8-3.9 (1H, m), 4. 2-4.5 (1H, m), 5.30 (2H, d, J = 2Hz), 5.9-6.1 (1H, m), 7.18 (2H, d, J = 8Hz), 7.40 (1H, d, J = 11 Hz), 7.87 (2H, d, J = 8 Hz), 8.46 (1H, s).

4- [3-Fluoro-2- (4-methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate 5-bromo-3-fluoro 2- (4-Methanesulfonylphenoxymethyl) pyridine (26 mg, 72.2 μmol), 3-methyl-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) Using isopropyl 3,6-dihydro-2H-pyridine-1-carboxylate (25 mg, 79.4 μmol), the title compound (18 mg, 54% yield) was obtained as a yellow amorphous product in the same manner as in Example 1. It was.

FAB-MS (m / z): 463 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.05 (3H, d, J = 7 Hz), 1.28 (6H, d, J = 6 Hz), 2.7-2.9 (1H, m), 3.03 (3H, s), 3.35 (1H, dd, J = 3 Hz, 13 Hz), 3.90 (1H, dd, J = 3 Hz, 13 Hz), 3.9-4.0 (1H, m ), 4.2-4.5 (1H, m), 4.9-5.1 (1H, m), 5.31 (2H, d, J = 2 Hz), 5.9-6.1 (1H M), 7.17 (2H, d, J = 8 Hz), 7.40 (1H, dd, J = 1 Hz, 11 Hz), 7.87 (2H, d, J = 8 Hz), 8.46 (1H) , S).

4- [3-Fluoro-2- [2,6-difluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1 -T-butyl carboxylate

(1) 5-Bromo-2-[(t-butyldimethylsilyloxy) methyl] -3-fluoropyridine (5-bromo-3-fluoropyridin-2-yl) methanol (300 mg, 1.46 mmol) was added to anhydrous dimethyl Dissolved in formamide (15 mL), triethylamine (0.3 mL, 2.91 mmol) and t-butyldimethylchlorosilane (241 mg, 1.60 mmol) were added. After stirring at room temperature for 4 hours, water was added and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 32: 1 → 1: 1) to give the title compound (386 mg, yield 83%) as a pale-yellow oil.

¹ H NMR (CDCl ₃ , 400 MHz) δ: 0.11 (6H, s), 0.90 (9H, s), 4.82 (2H, d, J = 1 Hz), 7.57 (1H, dd, J = 1 Hz, 8 Hz), 8.46 (1 H, s).

(2) 4- [2-[(t-Butyldimethylsilyloxy) methyl] -3-fluoropyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylic acid t- Butyl 5-bromo-2-[(t-butyldimethylsilyloxy) methyl] -3-fluoropyridine obtained above (342 mg, 1.07 mmol), 3-methyl-4- (4,4,5,5- Tetramethyl-1,3,2-dioxaborolan-2-yl) -3,6-dihydro-2H-pyridine-1-carboxylate t-butyl (380 mg, 1.18 mmol) and the same procedure as in Example 1 Gave the title compound (363 mg, 78% yield) as a colorless oil.

¹ H NMR (CDCl ₃ , 400 MHz) δ: 0.12 (6H, s), 0.91 (9H, s), 1.03 (3H, d, J = 7 Hz), 1.49 (9H, s) , 2.7-2.9 (1H, m), 3.30 (1H, dd, J = 3 Hz, 13 Hz), 3.85 (1H, dd, J = 3 Hz, 13 Hz), 3.8-4. 0 (1H, m), 4.2-4.5 (1 H, m), 4.86 (2 H, d, J = 2 Hz), 5.9-6.0 (1 H, m), 7.30 ( 1H, dd, J = 1 Hz, 11 Hz), 8.38 (1H, s).

(3) 4- (3-Fluoro-2-hydroxymethylpyridin-5-yl) -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate obtained above under nitrogen atmosphere 4- [2-[(t-Butyldimethylsilyloxy) methyl] -3-fluoropyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl (363 mg , 0.831 mmol) was dissolved in anhydrous tetrahydrofuran (8.3 mL), and tetrabutylammonium fluoride (1 mol / L tetrahydrofuran solution, 1 mL, 0.998 mmol) was added. After stirring at room temperature for 1 hour, water was added and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 15: 1 → 2: 1) to give the title compound (241 mg, yield 90%) as a colorless oil.

¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.03 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.31 ( 1H, dd, J = 3 Hz, 13 Hz), 3.75 (1 H, br s), 3.85 (1 H, dd, J = 3 Hz, 13 Hz), 3.8-4.0 (1 H, m), 4 2-4.5 (1H, m), 4.83 (2H, s), 5.9-6.0 (1H, m), 7.33 (1H, dd, J = 1 Hz, 11 Hz), 8 .38 (1H, s).

(4) t-Butyl 4- [3-fluoro-2- (methanesulfonyloxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate obtained above 4- (3-Fluoro-2-hydroxymethylpyridin-5-yl) -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl (241 mg, 0.748 mmol) was added to methylene chloride ( 7.5 mL), and triethylamine (0.16 mL, 1.12 mmol) was added under ice cooling. Subsequently, a methylene chloride solution of methanesulfonyl chloride (0.07 mL, 0.897 mmol) was added dropwise at the same temperature. After stirring at room temperature for 2 hours, the solvent was distilled off under reduced pressure. Saturated aqueous sodium hydrogen carbonate solution was added to the residue, and the mixture was extracted with chloroform. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to give the title compound (290 mg, yield 97%) as a red-purple oil.

¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.04 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.11 ( 3H, s), 3.31 (1H, dd, J = 3 Hz, 13 Hz), 3.86 (1H, dd, J = 3 Hz, 13 Hz), 3.8-4.0 (1H, m), 4. 2-4.5 (1 H, m), 5.40 (2 H, s), 6.0-6.1 (1 H, m), 7.40 (1 H, dd, J = 1 Hz, 11 Hz), 8. 46 (1H, s).

(5) 4- [3-Fluoro-2- [2,6-difluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H- T-butyl 2,6-difluoro-4- (tetrazol-1-yl) phenol (180 mg, 0.909 mmol) pyridine-1-carboxylate was dissolved in ethanol (2 mL) and 0.5 mol / L ethanolic hydroxylation was obtained. Potassium (0.45 mL, 0.909 mmol) was added. After stirring at room temperature for 30 minutes, the solvent was distilled off under reduced pressure to obtain potassium salt of 2,6-difluoro-4- (tetrazol-1-yl) phenol.
Under a nitrogen atmosphere, the obtained potassium salt (60 mg, 0.254 mmol) was dissolved in anhydrous dimethylformamide (2.0 mL) and 4- [3-fluoro-2- (methanesulfonyloxymethyl) pyridine- obtained above was dissolved. 5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl (102 mg, 0.254 mmol) in anhydrous dimethylformamide (0.5 mL) was added dropwise. The mixture was stirred at room temperature for 2 hours, further stirred at 50 ° C. for 3 hours, water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 3: 1) to give the title compound (50 mg, yield 39%) as white crystals.

FAB-MS (m / z): 503 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.04 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.31 ( 1H, dd, J = 3 Hz, 13 Hz), 3.85 (1H, dd, J = 3 Hz, 13 Hz), 3.8-4.0 (1H, m), 4.2-4.5 (1H, m ), 5.42 (2H, d, J = 2Hz), 5.9-6.1 (1H, m), 7.3-7.4 (2H, m), 7.40 (1H, dd, J = 2 Hz, 11 Hz), 8.42 (1H, s), 8.93 (1H, s).

4- [3-Fluoro-2- (2,6-difluoro-4-methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylic acid t- Butyl

(1) 5-Bromo-3-fluoro-2- (2,6-difluoro-4-methanesulfonylphenoxymethyl) pyridine 2,6-difluoro-4-methanesulfonylphenol (101 mg, 0.485 mmol) and 5-bromo The title compound (155 mg, yield 81%) was obtained in the same manner as in Example 3 (1) using -3-fluoropyridine-2-methanol (100 mg, 0.485 mmol).

¹ H NMR (CDCl ₃ , 400 MHz) δ: 3.06 (3H, s), 5.43 (2H, s), 7.4-7.6 (2H, m), 7.68 (1H, dd, J = 1 Hz, 9 Hz), 8.49 (1H, d, J = 1 Hz).

(2) 4- [3-Fluoro-2- (2,6-difluoro-4-methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carvone T-Butyl acid 5-bromo-3-fluoro-2- (2,6-difluoro-4-methanesulfonylphenoxymethyl) pyridine (50 mg, 0.126 mmol), 3-methyl-4- (4, obtained above) Performed with t-butyl 4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -3,6-dihydro-2H-pyridine-1-carboxylate (61 mg, 0.189 mmol) The title compound (27 mg, yield 41%) was obtained as a colorless oil in the same manner as in Example 1.

FAB-MS (m / z): 513 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.04 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.06 ( 3H, s), 3.30 (1H, dd, J = 4 Hz, 13 Hz), 3.8-4.0 (1H, m), 3.86 (1H, dd, J = 3 Hz, 13 Hz), 4. 1-4.5 (1H, m), 5.46 (2H, s), 6.03 (1H, br s), 7.39 (1H, dd, J = 2 Hz, 10 Hz), 7.4-7 .6 (2H, m), 8.41 (1H, s).

4- [3-fluoro-2- (2,6-difluoro-4-methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate < 5-Bromo-3-fluoro-2- (2,6-difluoro-4-methanesulfonylphenoxymethyl) pyridine (50 mg, 0.126 mmol), 3-methyl-4 obtained in Example 55 (1) -Using isopropyl (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -3,6-dihydro-2H-pyridine-1-carboxylate (59 mg, 0.189 mmol) The title compound (35 mg, yield 56%) was obtained as a colorless oil in the same manner as in Example 1.

FAB-MS (m / z): 499 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.04 (3H, d, J = 7 Hz), 1.2-1.4 (6H, m), 2.7-2.9 (1H, m), 3.06 (3H, s), 3.2-3.4 (1H, m), 3.8-4.0 (1H, m), 3.88 (1H, dd, J = 3 Hz, 13 Hz), 4.1-4.5 (1H, m), 4.9-5.1 (1H, m), 5.46 (2H, s), 6.02 (1H, br s), 7.39 (1H , Dd, J = 2 Hz, 10 Hz), 7.4-7.6 (2H, m), 8.41 (1H, s).

4- [2- (2,3-Difluoro-4-methanesulfonylphenoxymethyl) -3-fluoropyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylic acid t- Butyl 4- [3-Fluoro-2- (methanesulfonyloxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine obtained in Example 54 (4) In the same manner as in Example 31 using t-butyl-1-carboxylate (48 mg, 0.12 mmol) and 2,3-difluoro-4-methanesulfonylphenol (26 mg, 0.13 mmol), the title compound (6. 6 mg, yield 11%) was obtained as a white amorphous.

FAB-MS (m / z): 513 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.04 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.20 ( 3H, s), 3.2-3.5 (1H, m), 3.8-3.9 (2H, m), 4.2-4.5 (1H, m), 5.40 (2H, d, J = 1 Hz), 6.03 (1 H, br s), 7.13 (1 H, ddd, J = 2 Hz, 7 Hz, 9 Hz), 7.41 (1 H, dd, J = 2 Hz, 10 Hz), 7 .67 (1H, ddd, J = 2 Hz, 7 Hz, 9 Hz), 8.45 (1 H, s).

4- [3-Fluoro-2- [2-fluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carvone T-Butyl 2-fluoro-4- (tetrazol-1-yl) phenol (19 mg, 0.12 mmol) and 4- [3-fluoro-2- (methanesulfonyloxymethyl) pyridin-5-yl] -3 The title compound (45 mg, yield 88%) was prepared in the same manner as in Example 54 (5) using tert-butyl-methyl-3,6-dihydro-2H-pyridine-1-carboxylate (36 mg, 0.09 mmol). ) Was obtained as a white amorphous.

FAB-MS (m / z): 485 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.05 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.7-2.9 (1H, m), 3.2 3.4 (1H, m), 3.8-4.0 (2H, m), 4.2-4.5 (1H, m), 5.38 (2H, s), 6.03 (1H, br s), 7.3-7.5 (3H, m), 7.51 (1H, dd, J = 2 Hz, 11 Hz), 8.46 (1H, s), 8.94 (1H, s).

4- [3-Fluoro-2- [2-fluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carvone Isopropyl acid

(1) Isopropyl 4- [2-[(t-butyldimethylsilyloxy) methyl] -3-fluoropyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate 5-Bromo-2-[(t-butyldimethylsilyloxy) methyl] -3-fluoropyridine (323 mg, 1.01 mmol), 3-methyl-4- (4,4,5) obtained in Example 54 (1). , 5-tetramethyl-1,3,2-dioxaborolan-2-yl) -3,6-dihydro-2H-pyridine-1-carboxylate (374 mg, 1.21 mmol) and similar to Example 1. The title compound (155 mg, yield 36%) was obtained by the procedure.

¹ H NMR (CDCl ₃ , 400 MHz) δ: 0.12 (6H, s), 0.91 (9H, s), 1.04 (3H, d, J = 7 Hz), 1.2-1.3 ( 6H, m), 2.7-2.9 (1H, m), 3.3-3.4 (1H, m), 3.8-4.0 (2H, m), 4.1-4. 6 (1H, m), 4.86 (2H, s), 4.9-5.1 (1H, m), 5.99 (1H, br s), 7.30 (1H, d, J = 10 Hz) ), 8.39 (1H, s).

(2) 4- (2-Fluoro-2-hydroxymethylpyridin-5-yl) -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate 4- [2- [ With (t-butyldimethylsilyloxy) methyl] -3-fluoropyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate (155 mg, 0.367 mmol), The title compound (100 mg, yield 88%) was obtained as white crystals in the same manner as in Example 54 (3).

¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.04 (3H, d, J = 7 Hz), 1.2-1.4 (6H, m), 2.7-2.9 (1H, m), 3.3-3.5 (1H, m), 3.8-4.1 (3H, m), 4.2-4.5 (1H, m), 4.83 (2H, s), 4. 9-5.1 (1H, m), 5.98 (1H, brs), 7.35 (1H, d, J = 11 Hz), 8.39 (1H, s).

(3) 4- [3-Fluoro-2- [2-fluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine- Isopropyl 1-carboxylate 4- (3-Fluoro-2-hydroxymethylpyridin-5-yl) -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate obtained above (65 mg, 0 211 mmol) and 2-fluoro-4- (tetrazol-1-yl) phenol (37 mg, 0.170 mmol) in the same manner as in Example 54 (4) and Example 54 (5), and the title compound (41 mg Yield 51%) as a colorless oil.

FAB-MS (m / z): 471 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.05 (3H, d, J = 7 Hz), 1.2-1.3 (6H, m), 2.7-2.9 (1H, m), 3.3-3.4 (1H, m), 3.8-4.0 (2H, m), 4.2-4.5 (1H, m), 4.9-5.1 (1H, m ), 5.39 (2H, s), 6.04 (1H, br s), 7.3-7.5 (3H, m), 7.50 (1H, dd, J = 2 Hz, 11 Hz), 8 .46 (1H, s), 8.91 (1H, s).

4- [3-Fluoro-2- [2-fluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carvone Isopropyl hydrochloride 4- [3-Fluoro-2- [2-fluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl obtained in Example 59 The title compound (30 mg, yield 35%) was obtained as white crystals in the same manner as in Example 6 using isopropyl 3,6-dihydro-2H-pyridine-1-carboxylate (80 mg, 0.170 mmol). .

FAB-MS (m / z): 471 (M (free base) +1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.07 (3H, d, J = 7 Hz), 1.2-1.4 (6H, m), 2.7-2.9 (1H, m), 3.35 (1H, d, J = 13 Hz), 3.93 (1 H, d, J = 13 Hz), 3.9-4.0 (1 H, m), 4.3-4.6 (1 H, m ), 4.9-5.1 (1H, m), 5.56 (2H, s), 6.1-6.2 (1H, m), 7.4-7.6 (3H, m), 7.6-7.7 (1H, m), 8.54 (1H, s), 8.92 (1H, s).

4- [2- (2,3-difluoro-4-methanesulfonylphenoxymethyl) -3-fluoropyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate < Isopropyl 4- (3-fluoro-2-hydroxymethylpyridin-5-yl) -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate obtained in Example 59 (2) ( 58 mg, 0.188 mmol), 2,3-difluoro-4-methanesulfonylphenol (31 mg, 0.149 mmol) and the title compound (1) in the same manner as in Example 54 (4) and Example 54 (5). 0.5 mg, 2% yield) was obtained as a colorless oil.

FAB-MS (m / z): 499 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.05 (3H, d, J = 7 Hz), 1.2-1.4 (6H, m), 2.7-2.9 (1H, m), 3.20 (3H, s), 3.3-3.4 (1H, m), 3.8-4.1 (2H, m), 4.2-4.6 (1H, m), 4. 9-5.1 (1H, m), 5.40 (2H, s), 6.03 (1H, br s), 7.13 (1H, ddd, J = 2 Hz, 7 Hz, 9 Hz), 7.50 (1H, dd, J = 2 Hz, 11 Hz), 7.67 (1H, ddd, J = 2 Hz, 7 Hz, 9 Hz), 8.45 (1H, s).

4- [2- (4-Methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate 4 obtained in Example 1 -[2- (4-Methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl (26 mg, 0.0567 mmol) was used, The title compound (11 mg, yield 44%) was obtained as white crystals in the same manner as in Example 30.

FAB-MS (m / z): 445 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.03 (3H, d, J = 7 Hz), 1.2-1.4 (6H, m), 2.7-2.9 (1H, m), 3.03 (3H, s), 3.3-3.4 (1H, m), 3.8-4.0 (2H, m), 4.2-4.5 (1H, m), 4. 9-5.1 (1H, m), 5.27 (2H, s), 5.95 (1H, br s), 7.13 (2H, d, J = 9 Hz), 7.44 (1H, d , J = 8 Hz), 7.67 (1H, dd, J = 2 Hz, 8 Hz), 7.88 (2H, d, J = 9 Hz), 8.60 (1H, s).

4- [2- (4-Methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylic acid isopropyl hydrobromide Examples 4- [2- (4-Methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate obtained in 62 (100 mg, 0.225 mmol) Was used to give the title compound (67 mg, yield 57%) as white crystals in the same manner as in Example 2.

FAB-MS (m / z): 445 (M (free base) +1)
m. p. 155-159 ° C
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.07 (3H, d, J = 7 Hz), 1.2-1.4 (6H, m), 2.8-3.0 (1H, m), 3.05 (3H, s), 3.3-3.5 (1H, m), 3.8-4.1 (2H, m), 4.2-4.6 (1H, m), 4. 9-5.1 (1H, m), 5.83 (2H, s), 6.27 (1H, br s), 7.26 (2H, d, J = 9 Hz), 7.92 (2H, d , J = 9 Hz), 8.07 (1H, d, J = 8 Hz), 8.38 (1H, d, J = 8 Hz), 8.75 (1H, s).
IR (KBr, cm ⁻¹ ): 3003, 2979, 2924, 2873, 1697, 1651, 1595, 1558, 1498, 1427, 1387, 1296, 1246, 1180, 1142, 1109, 1041, 1041, 966, 918, 891 , 825, 773, 648, 619, 544, 488.

4- [2-[(6-Methanesulfonyl-2-methylpyridin-3-yl) oxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylic acid t -Butyl

(1) 5-bromo-2-[(6-methanesulfonyl-2-methylpyridin-3-yl) oxymethyl] pyridine 5-bromopyridine-2-methanol (47 mg, 0.25 mmol) was added to anhydrous dichloromethane (2. 5 mL), and triethylamine (21 μL, 0.27 mmol) and methanesulfonyl chloride (52 μL, 0.38 mmol) were added with stirring in a nitrogen atmosphere and an ice bath. After stirring at the same temperature for 1 hour, the reaction mixture was poured into saturated multistory water and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. Next, 3-hydroxy-6-methanesulfonyl-2-methylpyridine (50 mg, 0.27 mmol) was dissolved in dimethylformamide (2.5 mL), and sodium hydride (12 mg, 0) was added in a nitrogen atmosphere and an ice bath. .3 mmol) was added. After stirring at the same temperature for 15 minutes, the crude product of 5-bromo-2- (methanesulfonyloxymethyl) pyridine obtained above was dissolved in dimethylformamide (0.5 mL) and added dropwise. After stirring at room temperature for 16 hours, the reaction mixture was poured into saturated multistory water and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 1: 2) to give the title compound (68 mg, yield 76%) as white crystals.

¹ H NMR (CDCl ₃ , 400 MHz) δ: 2.62 (3H, s), 3.18 (3H, s), 5.25 (2H, s), 7.28 (1H, d, J = 8 Hz) 7.40 (1H, d, J = 8 Hz), 7.8-8.0 (2H, m), 8.68 (1H, d, J = 2 Hz).

(2) 4- [2-[(6-Methanesulfonyl-2-methylpyridin-3-yl) oxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridin-1- T-Butyl carboxylate Obtained above, 5-bromo-2-[(6-methanesulfonyl-2-methylpyridin-3-yl) oxymethyl] pyridine (30 mg, 0.084 mmol) and 3-methyl-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -3,6-dihydro-2H-pyridine-1-carboxylate t-butyl (33 mg, 0.10 mmol) The title compound (12 mg, 30% yield) was obtained as a pale yellow amorphous in the same manner as in Example 1.

FAB-MS (m / z): 474 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.04 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.63 (3H, s), 2.7-2.9 ( 1H, m), 3.18 (3H, s), 3.3-3.4 (1H, m), 3.8-4.0 (2H, m), 4.2-4.5 (1H, m), 5.30 (2H, s), 5.96 (1H, br s), 7.28 (1H, d, J = 8 Hz), 7.43 (1H, d, J = 8 Hz), 7. 68 (1H, dd, J = 2 Hz, 8 Hz), 7.89 (1 H, d, J = 8 Hz), 8.59 (1H, d, J = 2 Hz).

4- [2-[(6-Methanesulfonyl-2-methylpyridin-3-yl) oxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylic acid t -Butyl hydrochloride 4- [2-[(6-Methanesulfonyl-2-methylpyridin-3-yl) oxymethyl] pyridin-5-yl] -3-methyl-3 obtained in Example 64 , 6-Dihydro-2H-pyridine-1-carboxylate t-butyl (132 mg, 0.279 mmol) was used to give the title compound (146 mg, quantitative) as pale yellow crystals in the same manner as in Example 6.

FAB-MS (m / z): 474 (M (free base) +1)
m. p. : 152-154 ° C
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.08 (3H, d, J = 5 Hz), 1.51 (9H, s), 2.64 (3H, s), 2.7-2.9 ( 1H, m), 3.19 (3H, s), 3.3-3.4 (1H, m), 3.8-4.1 (2H, m), 4.2-4.6 (1H, m), 5.82 (2H, s), 6.24 (1H, br s), 7.50 (1H, d, J = 8 Hz), 7.9-8.1 (2H, m), 8. 35 (1H, d, J = 7 Hz), 8.68 (1H, br s).
IR (KBr, cm ⁻¹ ): 3012, 2976, 2925, 2897, 2360, 2087, 1984, 1699, 1651, 1562, 1446, 1410, 1368, 1313, 1267, 1247, 1167, 1134, 1115, 1007, 964 , 858, 827, 773, 563, 534, 494.

4- [2-[(6-Methanesulfonyl-2-methylpyridin-3-yl) oxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate 5-Bromo-2-[(6-methanesulfonyl-2-methylpyridin-3-yl) oxymethyl] pyridine (60 mg, 0.168 mmol), 3-methyl obtained in Example 64 (1) -4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -3,6-dihydro-2H-pyridine-1-carboxylate (57 mg, 0.185 mmol) The title compound (41 mg, 53% yield) was obtained as a pale yellow oil in the same manner as in Example 1.

FAB-MS (m / z): 460 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.03 (3H, d, J = 7 Hz), 1.2-1.4 (6H, m), 2.62 (3H, s), 2.7- 3.0 (1H, m), 3.18 (3H, s), 3.3-3.5 (1H, m), 3.8-4.0 (2H, m), 4.1-4. 5 (1H, m), 4.9-5.1 (1H, m), 5.29 (2H, s), 5.96 (1H, br s), 7.29 (1H, d, J = 8 Hz) ), 7.43 (1H, d, J = 8 Hz), 7.68 (1H, dd, J = 2 Hz, 8 Hz), 7.89 (1H, d, J = 8 Hz), 8.59 (1H, s) ).

3-methyl-4- [2- [2-methyl-6- (1,2,4-triazol-1-yl) pyridin-3-yloxymethyl] pyridin-5-yl] -3,6-dihydro- 2H-Pyridine-1-carboxylate t-butyl 4- [2- (methanesulfonyloxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl Example 29 (1) and implementation using (74 mg, 0.18 mmol) and 3-hydroxy-2-methyl-6- (1,2,4-triazol-1-yl) pyridine (37 mg, 0.21 mmol). The title compound (22 mg, yield 28%) was obtained as a brown amorphous substance in the same manner as in Example 29 (3).

FAB-MS (m / z): 463 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.03 (3H, d, J = 7 Hz), 1.50 (9H, s), 2.59 (3H, s), 2.7-3.0 ( 1H, m), 3.2-3.4 (1H, m), 3.7-4.0 (2H, m), 4.1-4.5 (1H, m), 5.26 (2H, s), 5.95 (1H, br s), 7.33 (1H, d, J = 9 Hz), 7.48 (1H, d, J = 8 Hz), 7.64 (1H, d, J = 9 Hz) ), 7.68 (1H, dd, J = 2 Hz, 8 Hz), 8.04 (1 H, s), 8.60 (1 H, d, J = 2 Hz), 9.07 (1 H, s).

3-ethyl-4- [2- (4-methanesulfonylphenoxymethyl) pyridin-5-yl] -3,6-dihydro-2H-pyridine-1-carboxylate t-butyl 5-bromo-2- (4- Methanesulfonylphenoxymethyl) pyridine (30 mg, 0.089 mmol) and 3-ethyl-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -3,6-dihydro The title compound (23 mg, 55% yield) was obtained as a pale yellow amorphous product in the same manner as in Example 1 using t-butyl -2H-pyridine-1-carboxylate (30 mg, 0.089 mmol).

FAB-MS (m / z): 473 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 0.94 (3H, t, J = 7 Hz), 1.2-1.6 (2H, m), 1.50 (9H, s), 2.5- 2.6 (1H, m), 3.00 (3H, s), 3.1-3.2 (1H, m), 3.7-3.9 (1H, m), 4.1-4. 2 (1H, m), 4.2-4.5 (1H, m), 5.26 (2H, s), 5.95 (1H, s), 7.12 (2H, d, J = 9 Hz) , 7.42 (1H, d, J = 8 Hz), 7.64 (1H, dd, J = 2 Hz, 8 Hz), 7.86 (2H, d, J = 9 Hz), 8.58 (1H, d, J = 2 Hz).

2- [4- [3-Chloro-2- [2-fluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine- 1-yl] -5-ethylpyrimidine 4- [3-Chloro-2- [2-fluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl obtained in Example 29 ] The title compound (2.5 mg, yield) was obtained in the same manner as in Example 51 using tert-butyl (3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate (30 mg, 0.064 mmol)). 8%) was obtained as a white amorphous.

FAB-MS (m / z): 507 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.08 (3H, d, J = 7 Hz), 1.21 (3H, t, J = 8 Hz), 2.49 (2H, q, J = 8 Hz), 2.9-3.0 (1H, m), 3.5-3.7 (1H, m), 4.0-4.2 (1H, m), 4.3-4.4 (1H, m ), 4.5-4.7 (1H, m), 5.44 (2H, s), 6.16 (1H, t, J = 3 Hz), 7.35 (1H, t, J = 8 Hz), 7.3-7.5 (1H, m), 7.50 (1H, dd, J = 2 Hz, 11 Hz), 7.74 (1H, d, J = 2 Hz), 8.22 (2H, s), 8.56 (1H, d, J = 2 Hz), 8.90 (1H, s).

3-Chloro-2- [2-fluoro-4- (tetrazol-1-yl) phenoxymethyl] -5- [1- (5-isopropyl-1,2,4-oxadiazol-3-yl) -3 -Methyl-3,6-dihydro-2H-pyridin-4-yl] pyridine

(1) 4- [3-Chloro-2- [2-fluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine- 1-carbonitrile 4- [3-Chloro-2- [2-fluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6 obtained in Example 29 -Dihydro-2H-pyridine-1-carboxylate t-butyl (78 mg, 0.17 mmol) was dissolved in dichloromethane (0.8 mL), trifluoroacetic acid (0.8 mL) was added, and the mixture was stirred at room temperature for 1 hour, The solvent was distilled off under reduced pressure.
Of the resulting 4- [3-chloro-2- [2-fluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine The crude was dissolved in dichloromethane (0.8 mL) and a solution of sodium bicarbonate (28 mg, 0.33 mmol) in water (0.4 mL) was added. Under ice-cooling, a solution of cyanogen bromide (21 mg, 0.20 mmol) in dichloromethane (0.8 mL) was added and stirred for 30 minutes, and further stirred at room temperature for 2 hours. The reaction mixture was poured into saturated multistory water and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 1: 1) to give the title compound (38 mg, yield 53%) as a colorless transparent oil.

¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.16 (3H, d, J = 7 Hz), 2.8-3.0 (1H, m), 3.2-3.4 (1H, m), 3.4-3.6 (1H, m), 3.9-4.1 (2H, m), 5.44 (2H, s), 5.95 (1H, t, J = 3 Hz), 7. 33 (1 H, t, J = 8 Hz), 7.4-7.5 (1 H, m), 7.51 (1 H, dd, J = 2 Hz, 10 Hz), 7.68 (1 H, d, J = 2 Hz) ), 8.49 (1H, d, J = 2 Hz), 8.92 (1H, s).

(2) 3-Chloro-2- [2-fluoro-4- (tetrazol-1-yl) phenoxymethyl] -5- [1- (5-isopropyl-1,2,4-oxadiazol-3-yl) ) -3-Methyl-3,6-dihydro-2H-pyridin-4-yl] pyridine 4- [3-Chloro-2- [2-fluoro-4- (tetrazol-1-yl) phenoxymethyl] obtained above ] Pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridin-1-carbonitrile (38 mg, 0.32 mmol) and Example 19 (1) and Example 19 (2) In the same manner, the title compound (15 mg, yield 33%) was obtained as a white amorphous.

FAB-MS (m / z): 511 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.10 (3H, d, J = 7 Hz), 1.37 (6H, d, J = 7 Hz), 2.8-3.0 (1H, m), 3.0-3.2 (1H, m), 3.5-3.6 (1H, m), 3.7-3.9 (1H, m), 3.9-4.1 (1H, m ), 4.2-4.3 (1H, m), 5.44 (2H, s), 6.09 (1H, t, J = 3 Hz), 7.34 (1H, t, J = 8 Hz), 7.4-7.5 (1 H, m), 7.51 (1 H, ddd, J = 2 Hz, 3 Hz, 8 Hz), 7.72 (1 H, d, J = 2 Hz), 8.54 (1 H, d , J = 2 Hz), 8.91 (1H, s).

5-ethyl-2- [4-[(4-methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridin-1-yl] pyrimidine obtained in Example 1. Using t-butyl 4- [2- (4-methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate (25 mg, 0.055 mmol) The title compound (12 mg, yield 74%) was obtained as a white amorphous product in the same manner as in Example 51.

FAB-MS (m / z): 465 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.06 (3H, d, J = 7 Hz), 1.21 (3H, t, J = 7 Hz), 2.48 (2H, q, J = 7 Hz), 2.9-3.1 (1H, m), 3.03 (3H, s), 3.6-3.7 (1H, m), 4.0-4.2 (1H, m), 4. 3-4.4 (1H, m), 4.5-4.7 (1 H, m), 5.28 (2H, s), 6.10 (1 H, t, J = 3 Hz), 7.13 ( 2H, d, J = 9 Hz), 7.45 (1H, d, J = 8 Hz), 7.71 (1H, dd, J = 2 Hz, 8 Hz), 7.87 (2H, d, J = 9 Hz), 8.21 (2H, s), 8.64 (1H, d, J = 2 Hz).

5- [1- (5-Isopropyl-1,2,4-oxadiazol-3-yl) -3-methyl-3,6-dihydro-2H-pyridin-4-yl] -2- (4-methane Sulfonylphenoxymethyl) pyridine

(1) 4- [2- (4-Methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carbonitrile 4- [obtained in Example 1 Example using t-butyl 2- (4-methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate (35 mg, 0.076 mmol) The title compound (21 mg, yield 72%) was obtained as a white amorphous product in the same manner as in 70 (1).

¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.14 (3H, d, J = 7 Hz), 2.8-3.0 (1H, m), 3.03 (3H, s), 3.2 3.4 (1H, m), 3.4-3.6 (1H, m), 3.9-4.0 (2H, m), 5.28 (2H, s), 5.89 (1H, t, J = 3 Hz), 7.12 (2H, d, J = 9 Hz), 7.47 (1H, d, J = 8 Hz), 7.65 (1H, dd, J = 2 Hz, 8 Hz), 7. 88 (2H, d, J = 9 Hz), 8.57 (1H, d, J = 2 Hz).

(2) 5- [1- (5-Isopropyl-1,2,4-oxadiazol-3-yl) -3-methyl-3,6-dihydro-2H-pyridin-4-yl] -2- ( 4-Methanesulfonylphenoxymethyl) pyridine 4- [2- (4-Methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carbohydrate obtained above. The title compound (10 mg, yield 39%) was obtained as white crystals in the same manner as in Example 19 (1) and Example 19 (2) using nitrile (21 mg, 0.055 mmol).

FAB-MS (m / z): 469 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.09 (3H, d, J = 7 Hz), 1.37 (6H, d, J = 7 Hz), 2.9-3.0 (1H, m), 3.03 (3H, s), 3.0-3.2 (1H, m), 3.5-3.6 (1H, m), 3.7-3.8 (1H, m), 3. 9-4.1 (1H, m), 4.1-4.3 (1H, m), 5.28 (2H, s), 6.03 (1H, t, J = 3 Hz), 7.13 ( 2H, d, J = 9 Hz), 7.46 (1H, d, J = 8 Hz), 7.70 (1H, dd, J = 2 Hz, 8 Hz), 7.88 (2H, d, J = 9 Hz), 8.62 (1H, d, J = 2 Hz).

5-ethyl-2- [4- [2- [2-fluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine- 1-yl] pyrimidine 4- [2- [2-fluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro- obtained in Example 5 The title compound (10 mg, yield 25%) was obtained as a pale yellow amorphous product in the same manner as in Example 51 using t-butyl 2H-pyridine-1-carboxylate (40 mg, 0.086 mmol).

FAB-MS (m / z): 473 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.06 (3H, d, J = 7 Hz), 1.21 (3H, t, J = 7 Hz), 2.48 (2H, q, J = 7 Hz), 2.9-3.1 (1H, m), 3.6-3.7 (1H, m), 4.0-4.2 (1H, m), 4.3-4.4 (1H, m ), 4.5-4.7 (1H, m), 5.35 (2H, s), 6.10 (1H, t, J = 3 Hz), 7.23 (1H, t, J = 9 Hz), 7.3-7.5 (1H, m), 7.5-7.6 (2H, m), 7.74 (1H, d, J = 2 Hz), 8.22 (2H, s), 8. 64 (1H, d, J = 2 Hz), 8.90 (1H, s).

2- [2-Fluoro-4- (tetrazol-1-yl) phenoxymethyl] -5- [1- (5-isopropyl-1,2,4-oxadiazol-3-yl) -3-methyl-3 , 6-Dihydro-2H-pyridin-4-yl] pyridine

(1) 4- [2- [2-Fluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carbonitrile 4- [2- [2-Fluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1 obtained in Example 5 -The title compound (55 mg, 82% yield) was obtained as a white amorphous substance in the same manner as in Example 70 (1) using t-butyl carboxylate (80 mg, 0.17 mmol).

¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.14 (3H, d, J = 7 Hz), 2.8-3.0 (1H, m), 3.2-3.4 (1H, m), 3.4-3.6 (1H, m), 3.8-4.0 (2H, m), 5.34 (2H, s), 5.80 (1H, t, J = 3 Hz), 7. 23 (1H, t, J = 9 Hz), 7.41 (1H, ddd, J = 2 Hz, 3 Hz, 9 Hz), 7.5-7.6 (2H, m), 7.68 (1H, dd, J = 2Hz, 8Hz), 8.58 (1H, d, J = 2Hz), 8.92 (1H, s).

(2) 2- [2-Fluoro-4- (tetrazol-1-yl) phenoxymethyl] -5- [1- (5-isopropyl-1,2,4-oxadiazol-3-yl) -3- Methyl-3,6-dihydro-2H-pyridin-4-yl] pyridine 4- [2- [2-fluoro-4- (tetrazol-1-yl) phenoxymethyl] pyridin-5-yl] obtained above Using 3-methyl-3,6-dihydro-2H-pyridine-1-carbonitrile (55 mg, 0.14 mmol) in the same manner as in Example 19 (1) and Example 19 (2), the title compound ( 15 mg, 22% yield) was obtained as a white amorphous.

FAB-MS (m / z): 477 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.09 (3H, d, J = 7 Hz), 1.37 (6H, d, J = 7 Hz), 2.9-3.0 (1H, m), 3.0-3.2 (1H, m), 3.5-3.6 (1H, m), 3.7-3.8 (1H, m), 3.9-4.0 (1H, m ), 4.1-4.3 (1H, m), 5.34 (2H, s), 6.03 (1H, t, J = 3 Hz), 7.23 (1H, t, J = 9 Hz), 7.39 (1 H, m), 7.5-7.6 (2 H, m), 7.72 (1 H, dd, J = 2 Hz, 8 Hz), 8.62 (1 H, d, J = 2 Hz), 8.91 (1H, s).

4- [6- (2,3-difluoro-4-methanesulfonylphenoxymethyl) pyridazin-3-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl

(1) 3-Chloro-6- (2,3-difluoro-4-methanesulfonylphenoxymethyl) pyridazine 2,3-difluoro-4-methanesulfonylphenol (120 mg, 0.576 mmol) was dissolved in ethanol (6 mL). 0.5 mol / L ethanolic potassium hydroxide solution (1.0 mL, 0.519 mmol) was added. After stirring at room temperature for 2 hours, the solvent was distilled off under reduced pressure. The obtained crude product was dissolved in anhydrous dimethylformamide (6 mL), 3-bromomethyl-6-chloropyridazine (120 mg, 0.576 mmol) was added, and the mixture was stirred overnight at room temperature. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography to obtain the title compound (61 mg, yield: 32%).

¹ H NMR (CDCl ₃ , 400 MHz) δ: 3.21 (3H, s), 5.56 (2H, s), 7.04 (1H, ddd, J = 2 Hz, 7 Hz, 9 Hz), 7.63 ( 1H, d, J = 9 Hz), 7.70 (1H, ddd, J = 2 Hz, 7 Hz, 9 Hz), 7.75 (1H, d, J = 9 Hz).

(2) t-butyl 4- [6- (2,3-difluoro-4-methanesulfonylphenoxymethyl) pyridazin-3-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate 3-Chloro-6- (2,3-difluoro-4-methanesulfonylphenoxymethyl) pyridazine obtained above (24 mg, 0.0717 mmol), 3-methyl-4- (4,4,5,5-tetramethyl) -1,3,2-dioxaborolan-2-yl) -3,6-dihydro-2H-pyridine-1-carboxylate t-butyl (30 mg, 0.0928 mmol) in the same manner as in Example 1 The compound (3.4 mg, yield 10%) was obtained as white crystals.

FAB-MS (m / z): 496 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.14 (3H, d, J = 7 Hz), 1.50 (9H, s), 3.1-3.3 (1H, m), 3.20 ( 3H, s), 3.3-3.5 (1H, m), 3.7-4.2 (2H, m), 4.3-4.7 (1H, m), 5.58 (2H, s), 6.50 (1H, br s), 7.0-7.1 (1H, m), 7.6-7.7 (3H, m).

3-methyl-4- [6- [4- (1,2,4-triazol-1-yl) phenoxymethyl] pyridazin-3-yl] -3,6-dihydro-2H-pyridine-1-carboxylic acid t -Butyl

(1) 3-Chloro-6- [4- (1,2,4-triazol-1-yl) phenoxymethyl] pyridazine 4- (1,2,4-triazol-1-yl) phenol (120 mg,. 745 mmol) and 3-bromomethyl-6-chloropyridazine (154 mg, 0.742 mmol), and the title compound (88 mg, 41% yield) was obtained in the same manner as in Example 75 (1).

¹ H NMR (CDCl ₃ , 400 MHz) δ: 5.47 (2H, s), 7.1-7.2 (2H, m), 7.5-7.7 (3H, m), 7.73 ( 1H, d, J = 9 Hz), 8.08 (1H, s), 8.46 (1H, s).

(2) 3-Methyl-4- [6- [4- (1,2,4-triazol-1-yl) phenoxymethyl] pyridazin-3-yl] -3,6-dihydro-2H-pyridine-1- T-butyl carboxylate 3-chloro-6- [4- (1,2,4-triazol-1-yl) phenoxymethyl] pyridazine obtained above (36 mg, 0.125 mmol), 3-methyl-4- ( Using 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -3,6-dihydro-2H-pyridine-1-carboxylate t-butyl (53 mg, 0.164 mmol) The title compound (6.8 mg, yield 12%) was obtained as white crystals in the same manner as in Example 1.

FAB-MS (m / z): 449 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.15 (3H, d, J = 7 Hz), 1.50 (9H, s), 3.1-3.3 (1H, m), 3.3 3.6 (1H, m), 3.7-4.1 (2H, m), 4.3-4.7 (1H, m), 5.48 (2H, s), 6.48 (1H, br s), 7.1-7.2 (2H, m), 7.5-7.7 (4H, m), 8.08 (1H, s), 8.45 (1H, s).

(Reference Example 1)

4- [2- (4-Methanesulfonylphenoxymethyl) pyridin-5-yl] -3,6-dihydro-2H-pyridine-1-carboxylate t-butyl 4-methanesulfonylphenol under nitrogen atmosphere (27 mg, 0.155 mmol), 4-[(2-hydroxymethyl) pyridin-5-yl] -3,6-dihydro-2H-pyridine-1-carboxylate t-butyl (30 mg, 0.103 mmol), tri Phenylphosphine (41 mg, 0.155 mmol) was dissolved in anhydrous tetrahydrofuran, and diethyl azodicarboxylate (2.2 mol / L toluene solution, 0.07 mL, 0.155 mmol) was added dropwise under ice cooling. After stirring overnight at room temperature, water was added and the mixture was extracted with chloroform. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 1: 1 → 1: 3 and chloroform: methanol = 300: 1) to give the title compound (6.1 mg, yield 13%) as white Obtained as crystals.

FAB-MS (m / z): 445 (M + 1)
¹ H NMR (CDCl ₃ , 400 MHz) δ: 1.50 (9H, s), 2.5-2.6 (2H, m), 3.03 (3H, s), 3.6-3.7 ( 2H, m), 4.0-4.2 (2H, m), 5.27 (2H, s), 6.1-6.2 (1H, m), 7.11 (2H, d, J = 9 Hz), 7.43 (1H, d, J = 8 Hz), 7.69 (1H, dd, J = 2 Hz, 8 Hz), 7.87 (2H, d, J = 9 Hz), 8.64 (1H, br s).
IR (KBr, cm ⁻¹ ): 3003, 2979, 2921, 2854, 1697, 1653, 1593, 1498, 1456, 1410, 1365, 1296, 1238, 1169, 1140, 1111, 1061, 1038, 972, 860, 833 , 810, 773, 552, 528.

(Reference Example 2)

4- [2- (4-Methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methylpiperidine-1-carboxylate 4- [2- (4- (Methanesulfonylphenoxymethyl) pyridin-5-yl] -3-methyl-3,6-dihydro-2H-pyridine-1-carboxylate t-butyl (20 mg, 43.6 μmol) in methanol (0.2 mL) and tetrahydrofuran ( 0.2 mL), 5% palladium carbon (containing 50 wt% water, 2 mg) was added, and catalytic hydrogenation was performed at room temperature for 1 hour and 40 minutes at 1 atmosphere. The reaction mixture was filtered through celite, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 1: 1) to give the title compound (16 mg, yield 80%) as white crystals.

¹ H NMR (CDCl ₃ , 400 MHz) δ: 0.71 (3H, d, J = 7 Hz), 1.47 (9H, s), 1.63 (1H, dd, J = 3 Hz, 13 Hz), 2. 0-2.2 (2H, m), 2.7-2.9 (1H, m), 2.9-3.2 (2H, m), 3.03 (3H, s), 4.0- 4.5 (2H, m), 5.25 (2H, s), 7.12 (2H, d, J = 8 Hz), 7.42 (1H, d, J = 8 Hz), 7.50 (1H, dd, J = 1 Hz, 8 Hz), 7.87 (2H, d, J = 8 Hz), 8.44 (1H, d, J = 1 Hz).

Pharmacological experiment 1
(1) Construction of human GPR119 constant expression cell The human GPR119 gene (NM_178471) was purchased from ATCC (ATCC No. 10807349), and PCR amplification was performed so that a BamHI site was formed on the 5 ′ side and an ApaI site was formed on the 3 ′ side. (Primers: TCCTGGATCCatggaatcatctttctcatt, TCCTGGGCCCttagcccatcaactctgagc). PCR conditions are as follows. Single-stranded DNA in which double-stranded DNA was heat-denatured at 98 ° C. for 10 seconds per cycle using DNA polymerase (KOD-Plus-Ver.2; TOYOBO # KOD-211) and primers were denatured at 55 ° C. for 30 seconds. Followed by DNA extension reaction at 68 ° C. for 1 minute 15 seconds. This was repeated for 35 cycles. The PCR product was inserted as an insert into plasmid pcDNA5 / FRT / TO (Invitrogen # V6520-20), and the resulting plasmid was introduced into Flp-in T-Rex-293 cells (invitrogen # R780-07). The introduction method was performed according to the product protocol.

(2) Intracellular cAMP measurement method Human GPR119 constant expression cells prepared by the above method were seeded in a 96-well plate to a concentration of 1000 cells / well (the medium contains 10% fetal bovine serum (FBS), Dulbecco's Modified Eagle Medium (DMEM) medium was used). Twenty-four hours after seeding the cells, tetracyclin (invitrogen # Q10019) (final concentration 40 ng / mL) was added to induce hGPR119 expression. After 24 hours, the medium was discarded, and stimulation was performed at 37 ° C. for 30 minutes with assay buffer (0.5 mM IBMX PBS (−)) containing the test compound. The amount of intracellular cAMP was measured using a commercially available kit (HitHunter ^™ cAMP XS + Assay (GE Healthcare # 90007503)) and a measuring machine (FLUOstar Optima: BMG LABTECH). The test compound was dissolved in 100% DMSO and added at a final concentration of 1%.

Pharmacological experiment 2
Metabolic stability in human liver microsomes (test method)
In this study, the metabolic stability of the test compound in the human liver microsome reaction solution was examined. The test method is shown below.
In a polyethylene test tube, 0.25 mmol / L EDTA-0.25 mol / L potassium phosphate buffer (pH 7.4) 200 μL, water 197.5 μL, human liver microsome solution (10 mg protein / mL) 50 50 μL of a mixed solution of μL and NADPH (β-NADP: 25 mmol / L, G-6-P: 250 mmol / L, G-6-P DH: 20 units / mL, MgCl ₂ : 100 mmol / L) In addition, after preincubating at 37 ° C. for 10 minutes, 2.5 μL of a 200 μg / mL solution (DMSO or acetonitrile) of the test compound was added to initiate the reaction. After incubating at 37 ° C. for 10 minutes, the remaining test compound was measured by the HPLC-UV method, and the remaining rate was calculated with 0 minute as a reference (residual rate 100%).
(Test results)

  Table 1 shows the test results of GPR119 agonist activity and liver microsomal metabolic stability test of the comparative compounds described in Reference Examples 1 and 2 and the compound of the present invention described in Example 1.

N. T. T. et al. : Not tested

(Compound described in Example 24 of WO2010 / 013849)

  As is apparent from Table 1, the compound of the present invention described in Example 1 is a comparative compound or a 3-methylpiperidine derivative described in Reference Example 1 having no alkyl group at the 3-position of the 3,6-dihydro-2H-pyridine ring. As compared with a comparative compound described in Reference Example 2, it was revealed that the compound has excellent GPR119 agonist activity and liver microsomal metabolic stability.

  The test results of GPR119 agonist activity and liver microsome metabolic stability test of the compounds of the present invention described in Examples are shown in Tables 2 to 4.

N. T. T. et al. : Not tested

cAMP Assay EC ₅₀
++: <100 nM, +: 100 nM to 1000 nM, −:> 1000 nM

Residual rate after 10 minutes of liver microsomal metabolic stability test A: 50% or more, B: less than 50%

  From Tables 2 to 4, it was revealed that the compounds of the present invention have excellent GPR119 agonist activity and hepatic microsomal metabolic stability.

Claims (19)

The compound represented by the following general formula (I), or a pharmaceutically acceptable salt thereof.

(In the formula, Ar represents a halogen atom, a nitro group, a cyano group, a hydroxy group, a C _1-8 alkyl group, a C _1-8 alkoxy group, a C _1-8 alkyl group substituted with 1 to 3 halogen atoms, C _1-8 alkoxy group substituted with 1 to 3 halogen atoms, phenyloxy group, alkoxycarbonyl group (the carbon number of alkoxy is 1-8), carboxyl group, carbamoyl group, acyl group (the carbon number of alkyl is 1-8), alkylaminocarbonyl group (alkyl has 1 to 8 carbon atoms), dialkylaminocarbonyl group (alkyl has 2 to 12 carbon atoms), cycloalkylaminocarbonyl group (cycloalkyl has 3 to 8 membered rings) , Alkoxycarbonylmethylcarbonyl group (alkoxy has 1 to 8 carbon atoms), alkylsulfonylmethyl group (alkyl has 1 to 8 carbon atoms), Mino group, C _1-8 alkylamino group, C _2-12 dialkylamino group, C _1-8 alkylsulfonylamino group, acylamino group (the alkyl has 1 to 8 carbon atoms), C _1-8 alkylsulfinyl group, C _1-8 alkylsulfonyl group, cycloalkylsulfonyl group (cycloalkyl is a 3- to 8-membered ring), sulfamoyl group, C _1-8 alkylaminosulfonyl group, C _2-12 dialkylaminosulfonyl group, phenylsulfonyl group and substituent Represents an aryl group which may be substituted with a substituent selected from a 5- or 6-membered heteroaryl group which may have, or a 5- or 6-membered heteroaryl group;
A represents (CH ₂ ) _m , O, NR ⁶ or a bond,
Here, m represents an integer of 1 to 3, R ⁶ represents a hydrogen atom or a C _1-8 alkyl group,
B represents (C (R ⁷ ) H) _n , O or NR ⁸ ;
Here, n represents an integer of 1 to 3, and R ⁷ and R ⁸ represent a hydrogen atom or a C _1-8 alkyl group.
However, when A is O, NR ⁶ or a bond, B is not O or NR ⁸ .
One of X and Y is N and the other is CR ⁹ or X and Y are both N;
Here, R ⁹ is a hydrogen atom, a halogen atom, a hydroxy group, a C _1-8 alkyl group, a C _1-8 alkoxy group, a C _1-8 alkyl group substituted with 1 to 3 halogen atoms, or 1 to 3 _Represents a C _1-8 alkoxy group substituted with one halogen atom,
R ¹ represents C (O) OR ¹⁰ , C (O) R ¹¹ , SO ₂ R ¹² , C (O) NR ¹³ R ¹⁴ , CH ₂ C (O) N (R ¹⁵ ) (R ¹⁶ ), Or a halogen atom, a C _1-8 alkyl group, a C _1-8 alkoxy group, a C _1-8 alkyl group substituted with 1 to 3 halogen atoms, and a C ₁ -substituted with 1 to 3 halogen atoms. _A 5- or 6-membered heteroaryl group which may have a substituent selected from ₈ alkoxy groups (the heteroaryl ring has a carbon atom and a nitrogen atom as ring-constituting atoms, and also has an oxygen atom And may be bonded to the nitrogen atom of the 3,6-dihydro-2H-pyridine ring via the carbon atoms constituting the ring),
Here, R ¹⁰ , R ¹¹ , R ¹² , R ¹³ , R ¹⁴ , R ¹⁵ and R ¹⁶ are C _1-8 alkyl, C _2-8 alkenyl group, C _3-8 cycloalkyl group, phenyl group or phenyl group. _Represents a C _1-8 alkyl group substituted with
R ² represents a C _1-8 alkyl group,
R ³ represents a hydrogen atom or a C _1-8 alkyl group,
R ⁴ and R ⁵ may be the same or different, and may be a hydrogen atom, a halogen atom, a hydroxy group, a C _1-8 alkyl group, a C _1-8 alkoxy group, or a C substituted with 1 to 3 halogen atoms. _It represents a C _1-8 alkoxy group substituted with a _1-8 alkyl group or 1 to 3 halogen atoms. ) Ar is a halogen atom, nitro group, cyano group, hydroxy group, C _1-8 alkyl group, C _1-8 alkoxy group, C _1-8 alkyl group substituted with 1 to 3 halogen atoms, 1 to 3 C _1-8 alkoxy group, phenyloxy group, alkoxycarbonyl group (alkoxy has 1 to 8 carbon atoms), carboxyl group, carbamoyl group, acyl group (alkyl has 1 to 8 carbon atoms) substituted with a halogen atom of , Alkylaminocarbonyl group (alkyl has 1 to 8 carbon atoms), dialkylaminocarbonyl group (alkyl has 2 to 12 carbon atoms), cycloalkylaminocarbonyl group (cycloalkyl is 3 to 8 membered ring), alkoxycarbonylmethyl A carbonyl group (the alkoxy has 1 to 8 carbon atoms), an alkylsulfonylmethyl group (the alkyl has 1 to 8 carbon atoms), an amino group, C _1-8 alkylamino group, C _2-12 dialkylamino group, C _1-8 alkylsulfonylamino group, acylamino group (the alkyl has 1 to 8 carbon atoms), C _1-8 alkylsulfinyl group, C _1-8 It has an alkylsulfonyl group, a cycloalkylsulfonyl group (cycloalkyl is a 3- to 8-membered ring), a sulfamoyl group, a C _1-8 alkylaminosulfonyl group, a C _2-12 dialkylaminosulfonyl group, a phenylsulfonyl group, and a substituent. The compound according to claim 1, which is a phenyl group or pyridyl group optionally having 1 to 3 substituents selected from a 5- or 6-membered heteroaryl group, or a pharmaceutically acceptable salt thereof. Salt. Ar is a halogen atom, nitro group, cyano group, C _1-8 alkyl group, alkoxycarbonyl group (alkoxy has 1 to 8 carbon atoms), carboxyl group, alkylaminocarbonyl group (alkyl has 1 to 8 carbon atoms), It has a cycloalkylaminocarbonyl group (cycloalkyl is a 3-8 membered ring), an amino group, a C _1-8 alkylsulfonyl group, a cycloalkylsulfonyl group (cycloalkyl is a 3-8 membered ring), a sulfamoyl group, and a substituent. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, which is a phenyl group which may be substituted with a substituent selected from a heteroaryl group which may be optionally substituted. The compound according to claim 1, wherein A is O and B is CH ₂ , or a pharmaceutically acceptable salt thereof. X is N and Y is CH, The compound of Claims 1-4, or its pharmaceutically acceptable salt. Compounds of claims 1 to 5, wherein R ¹ is C (O) ^{OR 10,} or a pharmaceutically acceptable salt thereof. The compound according to claim 6, or a pharmaceutically acceptable salt thereof, wherein R ¹⁰ is a C _1-8 alkyl group. The compound according to claim 6, wherein R ¹⁰ is a C _3-5 alkyl group, or a pharmaceutically acceptable salt thereof. R ¹ is a 3-C _1-8 alkyl-1,2,4-oxadiazol-5-yl group, a 5-C _1-8 alkyl-1,2,4-oxadiazol-3-yl group, or 5 A compound according to claim 1, which is an ethylpyrimidin-2-yl group, or a pharmaceutically acceptable salt thereof. Compound of claims 1-9 wherein R ² is a methyl group, or a pharmaceutically acceptable salt thereof. The compound of claim 10 wherein R ³ is a hydrogen atom, or a pharmaceutically acceptable salt thereof. R ⁴ and a compound of claims 1-11, wherein R ⁵ is a hydrogen atom or a halogen atom, or a pharmaceutically acceptable salt thereof. The compound represented by the following general formula (II), or a pharmaceutically acceptable salt thereof.

(In the formula, Ar ⁰ is a halogen atom, a nitro group, a cyano group, a hydroxy group, a C _1-8 alkyl group, a C _1-8 alkoxy group, or a C _1-8 alkyl group substituted with 1 to 3 halogen atoms. C _1-8 alkoxy group substituted with 1 to 3 halogen atoms, phenyloxy group, alkoxycarbonyl group (alkoxy has 1 to 8 carbon atoms), carboxyl group, carbamoyl group, acyl group (carbon number of alkyl) 1-8), alkylaminocarbonyl group (alkyl has 1 to 8 carbon atoms), dialkylaminocarbonyl group (alkyl has 2 to 12 carbon atoms), cycloalkylaminocarbonyl group (cycloalkyl has 3 to 8 membered rings) ), Alkoxycarbonylmethylcarbonyl group (alkoxy has 1 to 8 carbon atoms), alkylsulfonylmethyl group (alkyl has 1 to 8 carbon atoms) Amino _{groups, C 1-8} alkylamino _{groups, C 2-12} dialkylamino _{groups, C 1-8} alkylsulfonylamino group, (1-8 carbon atoms in the _alkyl) acylamino _{groups, C 1-8} alkylsulfinyl groups, C _1-8 alkylsulfonyl group, cycloalkylsulfonyl group (cycloalkyl is a 3- to 8-membered ring), sulfamoyl group, C _1-8 alkylaminosulfonyl group, C _2-12 dialkylaminosulfonyl group, phenylsulfonyl group and substituent 1 to 3 substituents selected from a 5- or 6-membered heteroaryl group which may have a phenyl group or a pyridyl group,
R ⁰ represents a C _1-8 alkyl group,
R ⁰² represents a C _1-8 alkyl group,
R ⁰⁴ and R ⁰⁵ may be the same or different, and may be a hydrogen atom, a halogen atom, a hydroxy group, a C _1-8 alkyl group, a C _1-8 alkoxy group, or a C substituted with 1 to 3 halogen atoms. _It represents a C _1-8 alkoxy group substituted with a _1-8 alkyl group or 1 to 3 halogen atoms. ) Ar ⁰ is a halogen atom, nitro group, cyano group, C _1-8 alkyl group, alkoxycarbonyl group (alkoxy has 1 to 8 carbon atoms), carboxyl group, alkylaminocarbonyl group (alkyl has 1 to 8 carbon atoms) , Cycloalkylaminocarbonyl group (cycloalkyl is a 3-8 membered ring), amino group, C _1-8 alkylsulfonyl group, cycloalkylsulfonyl group (cycloalkyl is a 3-8 membered ring), sulfamoyl group and substituent 14. The compound according to claim 13, or a pharmaceutically acceptable salt thereof, which is a phenyl group optionally substituted with a substituent selected from a 5-membered heteroaryl group which may optionally be substituted. The compound according to claim 13 or 14, or a pharmaceutically acceptable salt thereof, wherein R ⁰ is a C _3-5 alkyl group. The compound of claim 13 to 15, wherein R ⁰² is a methyl group, or a pharmaceutically acceptable salt thereof. ^R04 and ^R05 are a hydrogen atom or a halogen atom, The compound of Claims 13-16, or its pharmaceutically acceptable salt. A GPR119 agonist comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient. The therapeutic agent for diabetes which contains the compound of Claims 1-17, or its pharmaceutically acceptable salt as an active ingredient.